WO2020024916A1

WO2020024916A1 - Combination product of bcl-2 inhibitor or bcl-2/bcl-xl dual inhibitor and btk inhibitor and use thereof in the prevention and/or treatment of diseases

Info

Publication number: WO2020024916A1
Application number: PCT/CN2019/098252
Authority: WO
Inventors: Dajun Yang; Yifan Zhai; Douglas Dong Fang; Guangfeng Wang; Guoqin ZHAI
Original assignee: Ascentage Pharma Suzhou Co Ltd
Current assignee: Ascentage Pharma Suzhou Co Ltd
Priority date: 2018-07-31
Filing date: 2019-07-30
Publication date: 2020-02-06
Anticipated expiration: 2021-01-31
Also published as: CN114522167A; US20200222393A1; JP7085635B2; PL3672639T3; AU2019315487A1; GEAP202215448A; AU2019315487B2; MX2020009758A; EP3672639A1; UA125199C2; EP3672639A4; CA3094452A1; CN110772521A; GEP20237508B; BR112020019189A2; EA202091965A1; JP2021523091A; KR20200138724A; TWI758623B; US11478470B2

Abstract

Provided herein is a combination product comprising a Bcl-2 inhibitor (or a Bcl-2/Bcl-xl dual inhibitor) and a BTK inhibitor, the combination product providing a use in the prevention and/or treatment of a disease (e.g., cancer, autoimmune disease and inflammatory disease.).

Description

Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases

Technical field

The invention belongs to the technical field of medicine, and particularly relates to a combined product comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor and a use thereof in the prevention and/or treatment of a disease (for example, cancers, autoimmune diseases and inflammatory diseases) .

Background Art

Apoptosis (programmed cell death) is a natural pathway for the body to clear abnormal or unwanted cells, which can cause various diseases such as cancer if affected.

Anti-apoptotic Bcl-2 proteins are associated with many diseases. Bcl-2 family proteins are key regulators in the mitochondria-mediated apoptotic pathway. Escape from apoptosis is one of the characteristics of human cancer and is a common cause of clinical drug resistance.

Bruton's tyrosine kinase (BTK) belongs to the members of Tec family. It consists of a unique N-terminal domain, i.e., PH (pleckstrin homology) domain, a TH (Tec homology) homology domain, a SH3 (Src homology 3) domain, a SH2 (Src homology 2) domain, and a catalytic domain, also called SH 1/TK (Src homology 1 /Tyrosine kinase) domain or kinase domain (Akinley et al: Ibrutinib and novel BTK inhibitors in clinical development, Journal of Hematology & Oncology 2013, 6: 59) . During the normal development of B lymphocytes, the correct expression of different protein regions of BTK gene plays a key role in the function of B cells and various transduction pathways.

There are a variety of receptors at BTK function downstream, including growth factor, B cell antigen, chemokine, and innate immune receptor, which initiate a diverse range of cellular processes such as cell proliferation, survival, differentiation, movement, angiogenesis, cytokine production, antigen expression, and the like. Therefore, BTK plays an important role in many hematopoietic signaling pathways, and is also important in B cell activation, development, survival, and signaling (Kurosaki, Molecular mechanisms in B cell antigen receptor signaling. Curr OP Imm, 1997, 9 (3) : 309-18) .

Evidence for the role of BTK in autoimmune diseases has been provided by tests of BTK-deficient mice and BTK-sufficient mice model (Kil LP, et al: Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic Leukemia. Am J Blood Res 2013, 3 (1) : 71–83) . In a mouse model of chronic lymphocytic leukemia (CLL) , the BTK-deficient mice completely abolish chronic lymphocytic leukemia, and the overexpression of BTK accelerates the onset of leukemia and increases mortality.

With the advancement of molecular biology, molecular targeting therapy has become a hotspot in medical researches (especially tumor research) . The biological behavior of most tumors is not dominated by a single signaling pathway, but multiple signaling pathways. Thus, there is a need in the art for protocols and products for the combination of different target proteins and/or different signaling pathways that are capable of reducing the dose of single drug, reducing single drug side effects and/or acting in a synergistic manner for the purpose of preventing and/or treating diseases.

Contents of the Invention

In order to meet the needs in the prior art, the present invention provides a combination product comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor and its use in the treatment and/or prevention of a disease (for example, cancer, autoimmune disease and inflammatory disease) .

In particular, a first aspect of the invention relates to a combination product comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor.

In particular, another aspect of the invention relates to a method of treating a disease (e.g., cancer, autoimmune disease, and inflammatory disease) in a subject in need thereof, comprising administering a therapeutically effective amount of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor to the subject, wherein the subject is refractory or is resistant to a BTK inhibitor. In certain embodiments, the subject is refractory or is resistant to ibrutinib.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, or a pharmaceutically acceptable salt thereof:

wherein:

A ₃ is

E ₃ is a carbon atom and

is a double bond; or

E ₃ is a -C (H) -and

is a single bond; or

E ₃ is a nitrogen atom and

is a single bond;

X ³¹, X ³² and X ³³ are each independently selected from the group consisting of –CR ³⁸= and -N=;

R ^31a and R ^31b taken together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered optionally substituted aliphatic ring;

R ^31a and R ^31b taken together with the carbon atom to which they are attached form a 4-or 5-membered optionally substituted heterocyclo;

R ³² is selected from the group consisting of -NO ₂, -SO ₂CH ₃, and -SO ₂CF ₃;

R ^32a is selected from the group consisting of hydrogen and X;

R ³³ is selected from the group consisting of hydrogen, -CN, -C≡CH, and -N (R ^34a) (R ^34b) ;

R ^34a is selected from the group consisting of optionally substituted C _1-6 alkyl, optionally substituted C _3-6 cycloalkyl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl;

R ^34b is selected from the group consisting of hydrogen and C _1-4 alkyl;

R ³⁵ is selected from the group consisting of optionally substituted C _1-6 alkyl, heterocyclo, cycloalkylalkyl, and heterocycloalkyl;

R ^36a, R ^36c, R ^36e, R ^36f, and R ^36g are each independently selected from the group consisting of hydrogen, optionally substituted C _1-6 alkyl, optionally substituted C _3-6 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl;

R ^36b and R ^36d are each independently selected from the group consisting of hydrogen, C _1-4 alkyl, and halogen;

R ³⁷ is selected from the group consisting of optionally substituted C _1-6 alkyl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl;

R ³⁸ is selected from the group consisting of hydrogen and halogen.

In some embodiments, the Bcl-2 inhibitor is selected from the group consisting of a compound or a pharmaceutically acceptable salt or solvate thereof:

In some embodiments, the Bcl-2 inhibitor is the following compound or a pharmaceutically acceptable salt or solvate thereof:

In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is a compound of formula (I) , (II) , (III) or (IV) , or a pharmaceutically acceptable salt or solvate thereof:

wherein:

A ₁ ring is

X ₁₁, substituted or unsubstituted, is selected from the group consisting of alkylene, alkenylene, cycloalkylene, cycloalkenylene and heterocycloalkylene;

Y ₁₁ is selected from the group consisting of (CH ₂) _n-N (R ₁₁ ^a) ₂ and

Q ₁₁ is selected from the group consisting of O, O (CH ₂) _1-3, NR ₁₁ ^c, NR ₁₁ ^c (C _1-3 alkylene) , OC (=O) (C _1-3 alkylene) , C (=O) O, C (=O) O (C _1-3 alkylene) , NHC (=O) (C _1-3 alkylene) , C (=O) NH, and C (=O) NH (C _1-3 alkylene) ;

Z ₁₁ is O or NR ₁₁ ^c;

R ₁₁ and R ₁₂, independently, are selected from the group consisting of H, CN, NO ₂, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, OR ₁', SR ₁', NR ₁'R ₁″, COR ₁', CO ₂R ₁', OCOR ₁', CONR ₁'R ₁″, CONR ₁'SO ₂R ₁″, NR ₁'COR ₁″, NR ₁'CONR ₁″R ₁″′, NR ₁'C=SNR ₁″R ₁″′, NR ₁'SO ₂R ₁″, SO ₂R ₁', and SO ₂NR ₁'R ₁″;

R ₁₃ is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, OR ₁', NR ₁'R ₁″, OCOR ₁', CO ₂R ₁', COR ₁', CONR ₁'R ₁″, CONR ₁'SO ₂R ₁″, C _1-3 alkyleneCH (OH) CH ₂OH, SO ₂R ₁', and SO ₂NR ₁'R ₁″;

R ₁', R ₁″, and R ₁″′, independently are H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, C _1-3 alkyleneheterocycloalkyl, or heterocycloalkyl;

R ₁'and R ₁″, or R ₁″ and R ₁″′, can be taken together with the atom to which they are bound to form a 3 to 7-membered ring;

R ₁₄ is hydrogen, halo, C _1-3 alkyl, CF ₃, or CN;

R ₁₅ is hydrogen, halo, C _1-3 alkyl, substituted C _1-3 alkyl, hydroxyalkyl, alkoxy, or substituted alkoxy;

R ₁₆ is selected from the group consisting of H, CN, NO ₂, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, OR ₁', SR ₁', NR ₁'R ₁″, CO ₂R ₁', OCOR ₁', CONR ₁'R ₁″, CONR ₁'SO ₂R ₁″, NR ₁'COR ₁″, NR ₁'CONR ₁″R ₁″′, NR ₁'C=SNR ₁″R ₁″′, NR ₁'SO ₂R ₁″, SO ₂R ₁', and SO ₂NR ₁'R ₁″;

R ₁₇, substituted or unsubstituted, is selected form the group consisting of hydrogen, alkyl, alkenyl, (CH ₂) _0-3-cycloalkyl, (CH ₂) _0-3-cycloalkenyl, (CH ₂) _0-3-heterocycloalkyl, (CH ₂) _0-3-aryl, and (CH ₂) _0-3-heteroaryl;

R ₁₈ is selected form the group consisting of hydrogen, halo, NO ₂, CN, CF ₃SO ₂, and CF ₃;

R ₁₁ ^a is selected from the group consisting of hydrogen, alkyl, heteroalkyl, alkenyl, hydroxyalkyl, alkoxy, substituted alkoxy, cycloalkyl, cycloalkenyl, and heterocycloalkyl;

R ₁₁ ^b is hydrogen or alkyl;

R ₁₁ ^c is selected from the group consisting of hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxy, and substituted alkoxy; and

n ₁, r ₁, and s ₁, independently are 1, 2, 3, 4, 5, or 6;

R ₂₁ is SO ₂R ₂’;

R ₂₂ is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl;

R ₂₃ is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl;

R ₂₄ is halogen, preferably fluoride, chloride;

R ₂₅ is halogen, preferably fluoride, chloride;

R ₂₆ is selected from H, halogen and alkyl, preferably fluoride, chloride, C _1-4 alkyl, more preferably methyl, propyl, isopropyl;

R _21b is H or alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl;

n ₂, r ₂ and s ₂ are independently 1, 2, 3, 4, 5 or 6, more preferably, r ₂ and s ₂ are both 2 and n ₂ is 3, 4 or 5, more preferably, all of n ₂, r ₂ and s ₂ are 2, and R ₂' is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl.

In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is selected from the compounds of Table 2. In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is selected from the group consisting of Compound 72 and Compound 88.

In some embodiments, the BTK inhibitor is selected from the group consisting of: Ibrutinib, ICP-022, Acalabrutinib (ACP-196) , BGB3111, ONO/GS-4059, Spebrutinib (CC-292 or AVL-292) , CNX-774, Olmutinib (HM61713, BI1482694) , M7583, HM71224, PCI-32765 Racemate, GDC-0853, ONO-4059, Zanubrutinib, RN486, PCI-32765, CGI-1746, QL47, LFM-A13, (±) -Zanubrutinib, SNS-062, BMS-935177, Btk inhibitor 2, Evobrutinib, Ibrutinib-biotin, BMX-IN-1, GDC-0834 and CB1763.

In some embodiments, the combination product is in the form of a pharmaceutical composition.

In some embodiments, the Bcl-2 inhibitor and the BTK inhibitor are each in a separate preparation, or wherein the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are each in a separate preparation.

In some embodiments, the Bcl-2 inhibitor and the BTK inhibitor are administered simultaneously or sequentially, or wherein the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are administered simultaneously or sequentially.

In some embodiments, the combination product further comprises a pharmaceutically acceptable carrier, diluent or excipient.

In some embodiments, the combination product is in the form of tablet, capsule, granule, syrup, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol, ointment, cream and injection.

A second aspect of the invention relates to the use of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor in the manufacture of a medicament for the prevention and/or treatment of a disease selected from the group consisting of cancer, autoimmune disease and inflammatory disease.

A third aspect of the invention relates to a combination product for preventing and/or treating a disease, in which the combination product comprises a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor, and the disease is selected from the group consisting of cancer, autoimmune disease and inflammatory disease.

A fourth aspect of the invention relates to a method of preventing and/or treating a disease comprising administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor, wherein the disease is selected from cancer, autoimmune disease and inflammatory disease.

In some embodiments, the cancer is a hematological malignancy.

Preferably, the hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML) , acute lymphoblastic leukemia (ALL) , diffuse large B-cell lymphoma (DLBCL) , follicular lymphoma (FL) , chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) , marginal zone lymphoma (MZL) , chronic myelogenous leukemia (CML) , mantle cell lymphoma (MCL) , Waldenstrom’s macroglobulinemia (WM) , multiple myeloma (MM) , small cell lung cancer (SCLC) . More preferably, the hematological malignancy is diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) .

In some embodiments, the method of preventing and/or treating a disease, comprising administering the Bcl-2 inhibitor, the Bcl-2/Bcl-xL dual inhibitor or a pharmaceutically acceptable salt or solvate thereof in an amount of from about 0.0025 to 1500 mg per day.

In some embodiments, the method of preventing and/or treating a disease, comprising administering the BTK inhibitor or a pharmaceutically acceptable salt or solvate thereof in an amount of from about 0.0025 to 1000 mg per day.

Detailed Description of the Invention

Figure 1 shows the inhibitory effect of Ibrutinib alone and the combination of Ibrutinib and Compound 6 on proliferation in malignant tumor cells in WST experiment: OCI-LY8 (diffuse large B-cell lymphoma (DLBCL) ) , SU-DHL-4 (diffuse large B-cell lymphoma (DLBCL) ) , OCI-LY1 (diffuse large B-cell lymphoma (DLBCL) ) , DOHH2 (follicular lymphoma (FL) ) , RPMI-8226 (multiple myeloma (MM) ) , KMS-11 (multiple myeloma (MM) ) , Z-138 (mantle cell lymphoma (MCL) ) .

Figure 2 shows the anti-tumor effect (A) and body weight change (B) of Compound 6 alone or in combination with Ibrutinib in a human OCI-LY1 (diffuse large B-cell lymphoma (DLBCL) ) mouse xenograft tumor model.

Figure 3 shows the anti-tumor effect (A) and body weight change (B) of Compound 6 alone or in combination with Ibrutinib in a human DOHH2 (follicular lymphoma, FL) mouse xenograft tumor model.

Figure 4 shows the anti-tumor effect (A) and body weight change (B) of Compound 6 alone or in combination with Ibrutinib in a human DOHH2 (follicular lymphoma, FL) mouse xenograft tumor model.

Figure 5 shows the anti-tumor effects (A) and body weight change (B) of Compound 6 alone or in combination with Ibrutinib in a human OCI-LY1 (diffuse large B-cell lymphoma (DLBCL) ) mouse xenograft tumor model.

Figure 6 shows the synergistic inhibition of proliferation of FL (follicular lymphoma, FL) and DLBCL (diffuse large B-cell lymphoma (DLBCL) ) cells by combination treatment with Compound 6 and ibrutinib in vitro. Figure 6A and 6B represents the cell viability test from human FL DOHH-2 and DLBCL OCI-LY1, respectively.

Figure 7 shows the synergistic induction of apoptosis of FL (follicular lymphoma, FL) and DLBCL (diffuse large B-cell lymphoma (DLBCL) ) cells by combination treatment with Compound 6 and ibrutinib in vitro. Figure 7A shows Flow cytometry analysis of apoptotic cells by Annexin V and propidium iodide (PI) co-staining in DOHH-2 and OCI-LY1 cell lines treated with 10 nM (DOHH-2) or 15 nM (OCI-LY1)

Compound

6, 100 nM (DOHH-2) or 150 nM (OCI-LY1) ibrutinib, or the combination for 24 hours. Figure 7B shows the percentages of Annexin V-positive, PI-positive, or double positive DOHH-2 according to Figure 7A. Figure 7c shows the percentages of Annexin V-positive, PI-positive, or double positive OCI-LY1 according to Figure 7A.

Figure 8 shows the inhibitory effect of ibrutinib on the growth of DOHH2 cells and DOHH2 ^R-ibrutinib cells. DOHH2 ^R-ibrutinib cells shows resistance to ibrutinib.

Figure 9 shows the inhibitory effect of Compound 6 and ABT-199 on the growth of DOHH2 cells and DOHH2 ^R-ibrutinib cells.

Figure 10 shows the inhibitory effect of Compound 88 on the growth of DOHH2 cells and DOHH2 ^R-ibrutinib cells.

Definitions

The term "BTK inhibitor" as used herein refers to a substance that inhibits the activity of a BTK enzyme, or a substance that degrades a BTK enzyme, or a genetic tool that reduces the level of a BTK enzyme.

The term "resistance" as used herein refers to be resistant or non-responsive to a therapeutic agent (e.g., a BTK inhibitor, ibrutinib) . For example, the number of tumor cells still increases despite of receiving the treatment with a therapeutic agent.

The term "pharmaceutically acceptable salt" as used herein, refers to a salt of a free acid or a free base, usually prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the acid with a suitable organic or inorganic base. This term can be used in any of the compounds of the invention. Representative salts include: acetate, besylate, benzoate, bicarbonate, hydrogen sulfate, hydrogen tartrate, borate, bromide, calcium edetate, camphorsulfonate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, ethanedisulfonate, estolate, esylate, fumarate, glucoheptonate, gluconate, glutamate, glycol lylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, methanesulfonate, methylbroide, methylnitrate, methylsulfate, monopotassium maleate, mucate, naphthalenesulfonate, nitrate, N-methylglucosamine salt, oxalate, pamoate (dihydroxylnaphthalate) , palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, potassium salt, salicylate, sodium salt, stearate, subacetate, succinate, tannate, tartrate, teoclate, p-toluenesulfonate, triethiodide, trimethylamine salt and valerate. When an acidic substituent is present, such as -COOH, an ammonium salt, morpholine salt, sodium salt, potassium salt, barium salt, calcium salt or the like can be formed for use in a dosage form. When a basic group is present (for example, in a limonoid compound or a 1, 1-dimethylbiguanide) , such as an amino group or basic heteroaryl group such as a pyridyl group, an acidic salt can be formed, such as hydrochloride, hydrobromide, phosphate, sulfate, trifluoroacetate, trichloroacetate, acetate, oxalate, maleate, pyruvate, malonate, succinate, citrate, tartrate, fumarate, mandelate, benzoate, cinnamate, methanesulfonate, ethanesulfonate, picrate, and the like.

The term "prevention/preventing" as used herein refers to a compound or medicament (e.g, a combination product as claimed herein) can reduce a frequency of a symptom of a medical condition in a subject or delay the onset thereof when it is applied to a disease or condition (e.g., cancer) , in comparison with a subject to which the compound or medicament is not applied.

The term "treatment/treating" as used herein refers to reducing, alleviating or ameliorating a symptoms of a disease or condition, ameliorating a symptom caused by a potential metabolism, inhibiting a disease or symptom, such as preventing a disease or a disorder from progression, ameliorating a disease or condition, causing regression of a disease or condition, alleviating a condition caused by a disease or condition, or preventing a symptom of a disease or condition.

The term "cancer" as used herein refers to a new neoplasm or tumor caused by abnormal, uncontrolled cell growth. Non-limiting examples include those exemplary cancers described in the description of the invention. The term "cancer" includes diseases involving both pre-malignant cancer cells and malignant cancer cells.

The term "solvate" as used herein is a combination, physical binding, and/or solvation of a compound of the invention with a solvent molecule, such as a disolvate, a monosolvate, a hemisolvate. The compounds of the present invention may be in a solvate form with a pharmaceutically acceptable solvent such as water, methanol, ethanol, etc., which does not significantly affect the pharmacological activity or toxicity of the compounds and which may act as a pharmacological equivalent.

The term "subject" as used herein refers to including humans (e.g, patients) and animals (e.g, mice, rats, dogs, cats, rabbits, chickens, monkeys, etc. ) . When the subject is a human patient (usually calculated as body weight of 60 kg) , a dose described herein can be obtained by conversion performed with a conversion factor for an experimental animal (e.g, human dose = mouse dose /12.3) unless otherwise stated (Kin Tam. "Estimating the "First in human" dose-a revisit with particular emphasis on oncology drugs, ADMET & DMPK 1 (4) (2013) 63-75) . Those of ordinary skill in the art can reasonably adjust the dose based on common sense and according to the specific weight of subject, the type and severity of disease, and other factors, and all of these adjusted technical solutions fall within the scope of the technical solutions claimed in the present invention.

The term "effective amount" or "prophylactically and/or therapeutically effective amount" as used herein refers to a sufficient amount (e.g, a dose) of a medicament or compound to be administered that will alleviate one or more symptoms of a disease or condition to be treated to some extent. The result can be a reduction and/or alleviation in the cause of condition or disease or any other desired changes in biological system. For example, an "effective amount" for therapeutic use is an amount of a compound or medicament (e.g, a combination product as claimed herein) that provides a significant reduction in the clinical symptoms of the disease or condition without causing excessive toxic side effects.

The term "dose" as used herein refers to a weight (e.g, milligrams (mg) ) of an active substance per kilogram (kg) of a subject's body weight.

The term "IC ₅₀" as used herein refers to an amount, concentration or dose of a particularly tested compound or medicament that achieves a 50%inhibition of maximum effect in an assay that measures such effect, for example inhibition of BCL-2 or BTK.

The term "room temperature" as used herein refers to 25℃ ± 1℃. At the same time, if the experimental temperature is not specified, it is room temperature.

The term "about" as used herein refers to ±10%, more preferably ±5%, and most preferably ±2%of the value modified by the term, so that one of ordinary skill in the art can clearly determine the scope of the term "about" according to the modified value.

The terms "aliphatic ring" , "heterocycle" , "heterocycloalkyl" , "heteroalkyl" , "cycloalkylalkyl" and "halogen" as used herein have the ordinary meanings in the art, and a person of ordinary skill in the art will be able to understand the meaning thereof by the general knowledge or by reference to the prior art (for example, WO 2018/027097, the entire disclosure of which is incorporated herein by reference) .

The term "Ibrutinib" as used herein is a compound having the structure:

Detailed Description of the Invention

In a first aspect of the invention relates to a combination product comprising or consisting of a Bcl-2 inhibitor and a BTK inhibitor. In a first aspect of the invention relates to a combination product comprising or consisting of a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor.

In another aspect of the invention relates to a method of treating a disease (e.g., cancer, autoimmune disease, and inflammatory disease) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the Bcl-2 Inhibitor or the Bcl-2/Bcl-xL dual inhibitor, wherein the subject is refractory or is resistant to a BTK inhibitor. In certain embodiments, the subject is refractory or is resistant to ibrutinib.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, or a pharmaceutically acceptable salt or solvate thereof:

wherein:

A ₃ is

E ₃ is a carbon atom and

is a double bond; or

E ₃ is a -C (H) -and

is a single bond; or

E ₃ is a nitrogen atom and

is a single bond;

R ^32a is selected from the group consisting of hydrogen and X;

R ^34b is selected from the group consisting of hydrogen and C _1-4 alkyl;

R ³⁸ is selected from the group consisting of hydrogen and halogen.

In the above compound of Formula I-A, the “X” in the definition of variant R ^32a refers to halogen. Further, halogen mentioned above refers to F, Cl, Br, or I.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, wherein: A ₃ is selected from the group consisting of A-1, A-2, A-3, A-4, A-5, A-6, A-7, A-8, and A-9; R ^34a is selected from the group consisting of optionally substituted C _1-6 alkyl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl; R ^36a, R ^36c, R ^36e, R ^36f and R ^36g are each independently selected from the group consisting of hydrogen, optionally substituted C _1-6 alkyl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-b, or a pharmaceutically acceptable salt or solvate thereof,

wherein:

E ₃ is a carbon atom and

is a double bond; or E ₃ is -C (H) -and

is a single bond; or E ₃ is a nitrogen atom and

is a single bond;

R ^31a and R ^31b together with the carbon atom connected thereto form a 3-, 4-, or 5-membered optionally substituted aliphatic ring; or

R ^31a and R ^31b together with the carbon atom connected thereto form a 4-or 5-membered optionally substituted heterocyclo;

R ^34a is selected from the group consisting of optionally substituted C _1-6 alkyl, heterocyclo, cycloalkylalkyl, and heterocycloalkyl;

R ^34b is selected from the group consisting of hydrogen and C _1-4 alkyl.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-c, or a pharmaceutically acceptable salt or solvate thereof,

wherein :

Y ₃ is selected from the group consisting of -CH ₂-and -O-, and R ³² and R ^34a are as defined in connection with Formula I-b.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-d, or a pharmaceutically acceptable salt or solvate thereof,

wherein :

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-e, or a pharmaceutically acceptable salt or solvate thereof,

wherein :

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-f, or a pharmaceutically acceptable salt or solvate thereof,

wherein:

Y ₃ selected from the group consisting of -CH ₂-and -O-, and A ₃, X ³¹, X ³², and X ³³ are as defined in connection with Formula I-A.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-g, or a pharmaceutically acceptable salt or solvate thereof,

wherein

Y ₃ selected from the group consisting of -CH ₂-and -O-, and A ₃ is as defined in connection with Formula I-A.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-1.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-2.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-3.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-4.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-5.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-6.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-7.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-8.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-9.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein A ₃ is A-10.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-h, or a pharmaceutically acceptable salt or solvate thereof,

wherein

Y ₃ selected from the group consisting of -CH ₂-and -O-, and X ³¹, X ³², X ³³, R ³², and R ^34a are as defined in connection with Formula I-A.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein all X ³¹, X ³², and X ³³ -CH=.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein X ¹ is -CF=, and both X ³² and X ³³ are -CH=.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein both X ³¹ and X ³³ are -CH=, and X ³² is -CF=.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein both X ³¹ and X ³² are -CH=, and X ³³ is -CF=.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein X ³¹ is -N=, and both X ³² and X ³³ are -CH=.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein X ³¹ and X ³³ are each -CH=, and X ³² is -N=.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-A, I-f or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein both X ³¹ and X ³² are -CH=, and X ³³ is -N=.

In some embodiments, the Bcl-2 inhibitor is a compound of any one of Formulae I-c to I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein Y ₃ is -O-.

In some embodiments, the Bcl-2 inhibitor is a compound of any one of Formulae I-c to I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein Y ₃ is -CH ₂-.

In some embodiments, the Bcl-2 inhibitor is a compound of any one of Formulae I-A or I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein R ³² is -NO ₂.

In some embodiments, the Bcl-2 inhibitor is a compound of any one of Formulae I-g, or a pharmaceutically acceptable salt or solvate thereof, wherein R ^34a is selected from the group consisting of:

In some embodiments, the Bcl-2 inhibitor is a compound of any one of Formulae I-A or I-f to I-h, or a pharmaceutically acceptable salt or solvate thereof, wherein R ^34a, R ³⁵, R ^36a, and R ³⁷ are each independently selected from the group consisting of:

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-i, or a pharmaceutically acceptable salt or solvate thereof, wherein R ^32a is hydrogen or fluoro and R ^34a is as defined in connection with Formula I-A.

In some embodiments, the Bcl-2 inhibitor is a compound of Formula I-i, or a pharmaceutically acceptable salt or solvate thereof, wherein R ^34a is selected from the group consisting of:

In some embodiments, the Bcl-2 inhibitor is a compound selected from one or more of the compounds of Table 1, or a pharmaceutically acceptable salt or solvate thereof.

Table 1

In some embodiments, the Bcl-2 inhibitor is a compound selected from one or more of the compounds of Table 1-A, or a pharmaceutically acceptable salt or solvate thereof.

Table 1-A

In some embodiments, the Bcl-2 inhibitor is a compound selected from one or more of the compounds of Table 1-B, or a pharmaceutically acceptable salt or solvate thereof.

Table 1-B

wherein:

A ₁ ring is

Z ₁₁ is O or NR ₁₁ ^c;

R ₁', R ₁″, and R ₁″′, independently are H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, C _1-3alkyleneheterocycloalkyl, or heterocycloalkyl;

R ₁' and R ₁″, or R ₁″ and R ₁″′, can be taken together with the atom to which they are bound to form a 3 to 7-membered ring;

R ₁₄ is hydrogen, halo, C _1-3 alkyl, CF ₃, or CN;

R ₁₁ ^b is hydrogen or alkyl;

n ₁, r ₁, and s ₁, independently are 1, 2, 3, 4, 5, or 6;

R ₂₁ is SO ₂R ₂’;

R ₂₄ is halogen, preferably fluoride, chloride;

R ₂₅ is halogen, preferably fluoride, chloride;

n ₂, r ₂ and s ₂ are independently 1, 2, 3, 4, 5 or 6, more preferably, r ₂ and s ₂ are both 2 and n ₂ is 3, 4 or 5, more preferably, all of n ₂, r ₂ and s ₂ are 2, and

R ₂' is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl.

In the above formula (I) , (II) or (III) , in some embodiments, R ₁₁ and R ₁₂ or R ₁₂ and R ₁₃ may together form a ring. In other embodiments, R ₁' and R ₁" or R ₁" and R ₁"'may form a 3-7 membered ring together with the atoms to which they are attached.

In some preferred embodiments, X ₁₁ is an alkylene group, and in other preferred embodiments, a C _1-3 alkylene.

In some embodiments, Y ₁₁ is:

In a preferred embodiment, n ₁ is 2. In other preferred embodiments, R _11b is hydrogen or C _1-3 alkyl.

In some preferred embodiments, Q ₁₁ is O, O (CH ₂) _1-3, C (=O) O (CH ₂) _1-3, OC (=O) (CH ₂) _1-3 or C (=O) O (C ₃H ₇) _1-3. In other embodiments, Q ₁₁ is O, OCH ₂, C (=O) OCH ₂, C (=O) O (CH ₂) ₂, C (=O) O (CH ₂) ₃, OC (=O) CH ₂ or C (=O) O (CH (CH ₃) CH ₂) .

In some embodiments, Z ₁₁ is O, NH or N (C _1-3 alkyl) . In preferred embodiments, Z ₁₁ is O, NH or NCH _3.

In some embodiments, R ₁₁ is SO ₂R ₁', SO ₂NR ₁'R ₁", NR ₁'SOR ₁", H or alkyl. In some preferred embodiments, R ₁₁ is SO ₂ (C _1-3 alkyl) , SO ₂N (C _1-3 alkyl) ₂, NHSO ₂ (C _1-3 alkyl) , H or C _1-3 alkyl. A preferred embodiment of R ₁₁ is SO ₂CH _3.

In some embodiments, R ₁₂ and R ₁₃ are independently H, C _1-3 alkyl or cycloalkyl. R ₁₂ can also be halogen. In some preferred embodiments, R ₁₂ and R ₁₃ are independently methyl, ethyl, n-propyl, isopropyl, cyclopentyl or cyclohexyl. R ₁₂ can also be Cl or F.

In some embodiments, R ₁₄ is H or halo, preferably H, Cl or F. In other embodiments, R ₁₅ is H, halo or C _1-3 alkyl, preferably H, methyl, ethyl, n-propyl, isopropyl, F or Cl. In other embodiments, R ₁₆ is H, halo, alkyl or cycloalkyl. In some preferred embodiments, R ₁₆ is H, F, Cl, C _1-3 alkyl, cyclopentyl or cyclohexyl.

In some embodiments, R ₁₇ is (CH ₂) _0-3-cycloalkyl or (CH ₂) _0-3-heterocycloalkyl. In a preferred embodiment, R ₁₇ is (CH ₂) _0-3-cycloalkyl, optionally substituted by -OH. In one embodiment, R ₁₇ is

In some embodiments, R ₁₈ is CF ₃SO ₂ or CF ₃. In various embodiments, R _11a, R _11b, and R _11c are, independently, H or C _1-3 alkyl.

In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is selected from the compounds of Table 2 below, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

Table 2.

In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is (R) -2- (1- (3- (4- (N- (4- (4- (3- (2- (4-chlorophenyl) -1-isopropyl-5-methyl-4- (methylsulfonyl) -1H-pyrrol-3-yl) -5-fluorophenyl) piperazin-1-yl) phenyl) sulfamoyl) -2- (trifluoromethylsulfonyl) phenylamino) -4- (phenylthio) butyl) piperidine-4-carbonyloxy) ethylphosphonic acid (i.e. Compound 72 in the above table, sometimes abbreviated as "Compound 72" ) or a pharmaceutically acceptable salt thereof, as shown in the following structural formula:

Compound 72 selectively binds to Bcl-2, Bcl-xL, and Bcl-w proteins with high affinity, and the IC ₅₀ is 1.6 nM, 4.4 nM, and 9.3 nM, respectively. Compound 72 binds weakly to Mcl-1. Compound 72, by chemical structural modification, effectively reduces platelet toxicity defects in first-generation BCL-2 inhibitors in the blood circulation, yet is capable of obtaining specific enzyme activation in tissues to effectively kill tumor cells. Its platelet toxicity is reduced by 10-30 times, but the activity is about 10 times that of the first generation BCL-2 inhibitors. Compound 88 is an active metabolite of Compound 72. Compound 72 is a second generation new target BCL-2 protein inhibitor.

The Bcl-2/Bcl-xL dual inhibitor of the present invention may also preferably be (R) -1- (3- (4- (N- (4- (4- (3- (2- (4-chlorophenyl) ) -1-isopropyl-5-methyl-4- (methylsulfonyl) -1H-pyrrol-3-yl) -5-fluorophenyl) piperazin-1-yl) phenyl) -sulfamoyl-2- (trifluoromethylsulfonyl) phenylamino) -4- (phenylthio) butyl) piperidine-4-carboxylic acid (i.e., Compound 88 in the above table, sometimes abbreviated as "Compound 88" ) , or a pharmaceutically acceptable salt thereof, represented by the following structural formula:

The above Bcl-2/Bcl-xL dual inhibitor in the pharmaceutical composition of the present invention can be synthesized according to the method described in WO2014/113413A1.

Compounds of the above formula (I) , (II) or (III) have been disclosed in WO2014/113413A1, which is incorporated herein by reference to its entirety. The above general formula (IV) is disclosed in PCT/CN2019/070508, which is incorporated herein by reference to its entirety.

In some embodiments, the BTK inhibitor is selected from the group consisting of: Ibrutinib, ICP-022, Acalabrutinib (ACP-196) , BGB3111, ONO/GS-4059, Spebrutinib (CC-292 or AVL-292) , CNX-774, Olmutinib (HM61713, BI1482694) , M7583, HM71224, PCI-32765 Racemate, GDC-0853, ONO-4059, Zanubrutinib, RN486, PCI-32765, CGI-1746, QL47, LFM-A13, (±) -Zanubrutinib, SNS-062, BMS-935177, Btk inhibitor 2, Evobrutinib, Ibrutinib-biotin, BMX-IN-1, GDC-0834 and CB1763. Preferably, the BTK inhibitor is selected from the group consisting of: Ibrutinib, Acalabrutinib (ACP-196) and BGB3111. More preferably, the BTK inhibitor is Ibrutinib having the following structure:

In some embodiments, the Bcl-2 inhibitor and the BTK inhibitor are each in a separate preparation, or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are each in a separate preparation.

In some embodiments, the Bcl-2 inhibitor and the BTK inhibitor are administered simultaneously or sequentially, or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are administered simultaneously or sequentially.

In some embodiments, the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor may be administered sequentially at a time interval of about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 96 hours, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, About 5 weeks, about 6 weeks, about 8 weeks, or about 12 weeks.

In some embodiments, the combination product of the invention comprising the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor in the form of a pharmaceutical composition (preferably, each in a separate dosage unit form) , as desired, can be daily administered for, including but not limited to: 1 time, 2 times, 3 times, 4 times, 5 times or 6 times.

In some embodiments, the combination product of the invention comprising the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor in the form of a pharmaceutical composition (preferably, in the form of a dosage unit) , as desired, can be daily administered for, including but not limited to: 1 time, 2 times, 3 times, 4 times, 5 times or 6 times.

In some embodiments, the combination product can be administered in the following manner: oral, buccal, inhalation spray, sublingual, rectal, transdermal, vaginal mucosa, transmucosal, local, nasal or enteral administration; parenteral administration, such as intramuscular injection, subcutaneous injection, intramedullary injection, as well as intrathecal or brain direct administration, in situ administration, subcutaneous, intraperitoneal, intravenous injection, intra-articular synovium, intrasternal, intrahepatic, intralesional, intracranial, intra-abdominal, nasal, or intraocular injection or other drug delivery manners.

In some embodiments, the Bcl-2 inhibitor or a pharmaceutically acceptable salt or solvate thereof is administered in an amount of from about 0.0025 to 1500 mg/day. Preferably, the daily dose of the Bcl-2 inhibitor is 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 460 mg, 470 mg, 480 mg, 487 mg, 490 mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, 850mg, 900mg, 950mg, 1000mg, and a range between the respective doses, for example, 1mg to 1000mg, 30mg to 900mg, 30mg to 800mg, 30mg to 900mg, 30mg to 800mg, 30mg to 700mg, 30mg to 600mg, 30mg to 500mg, 30mg to 490mg, 30mg to 487mg, etc., and the BTK inhibitor or a pharmaceutically acceptable salt or solvate thereof is administered in an amount of about 0.0025 to 1000 mg/day. Preferably, the daily dose of the BTK inhibitor is 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 73 mg, 80 mg, 90 mg, 97.6 mg, 100 mg, 122 mg, 150 mg, 200 mg, 250mg, 300mg, 350mg, 400mg, 450mg, 460mg, 470mg, 480mg, 487mg, 490mg, 500mg, 550mg, 600mg, 650mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, and a range between the respective doses, for example, 10 mg to 1000 mg, 20 mg to 950 mg, 30 mg to 900 mg, 50 mg to 650 mg, 60 mg to 600 mg, 70 mg to 450 mg, 73 mg to 400 mg, 73 mg to 550 mg, 73 mg to 522 mg, 97.6 mg to 600 mg, 97.6 mg to 600 mg, 97.6 mg to 700 mg, 97.6 mg to 800 mg, 97.6 mg to 950 mg, 122 mg to 500 mg, 122 mg to 600 mg, 122 mg to 700 mg , 122mg to 800mg, 97.6mg to 900mg, 73mg to 1000mg, and the like.

In certain embodiments, the Bcl-2/Bcl-xL dual inhibitor may be administered in an amount of from about 0.005 to about 500 mg/day, preferably from about 0.05 to about 250 mg/day, more preferably from about 0.5 to about 100 mg/day. In certain embodiments, the Bcl-2/Bcl-xL dual inhibitor is administered in an amount of from about 10 mg/week to about 1000 mg/week, from about 10 mg/week to about 900 mg/week, from about 10 mg/week to about 800 mg/Week, about 10 mg/week to about 700 mg/week, about 10 mg/week to about 640 mg/week, about 10 mg/week to about 600 mg/week, about 10 mg/week to about 500 mg/week, about 10 mg/Weekly to about 400 mg/week, about 10 mg/week to about 300 mg/week, about 10 mg/week to about 200 mg/week, or about 20 mg/week to about 100 mg/week, for example about 10, 15, 20, 25, 30, 35, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 mg/week, and the BTK inhibitor or a pharmaceutically acceptable salt or solvate thereof is administered in an amount of from about 0.0025 to 1000 mg per day. In certain embodiments, the Bcl-2/Bcl-xL dual inhibitor is about 0.005, 0.05, 0.5, 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg. In certain embodiments, the Bcl-2/Bcl-xL dual inhibitor is administered at a frequency of once a week, twice a week, three times a week, four times a week, five times a week, six times a week, seven times a week.

Preferably, the daily dose of the BTK inhibitor is 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 73 mg, 80 mg, 90 mg, 97.6 mg, 100 mg, 122 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 460 mg, 470 mg, 480 mg, 487 mg, 490 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, and a range between the respective doses, for example, 10mg-1000mg, 20mg-950mg, 30mg-900mg, 50mg-650mg, 60mg-600mg, 70mg-450mg, 73mg-400mg, 73mg-550mg, 73mg-522mg, 97.6mg-600mg, 97.6mg-600mg, 97.6mg-700mg 97.6 mg-800 mg, 97.6 mg-950 mg, 122 mg-500 mg, 122 mg-600 mg, 122 mg-700 mg, 122 mg-800 mg, 97.6 mg-900 mg, 73 mg-1000 mg, and the like.

A second aspect of the invention relates to the use of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor in the manufacture of a medicament for the prevention and/or treatment of a disease selected from the group consisting of cancer, autoimmune disease and inflammatory disease. In some embodiments, the disease is refractory or is resistant to BTK inhibitors. In certain embodiments, the disease is refractory or is resistant to ibrutinib.

In some embodiments, the Bcl-2 inhibitor is a compound (e.g, Compound I-A, Compound I-b, Compound I-c, Compound I-d, Compound I-e, Compound I-f, Compound I-g, Compound I-h, Compound I-i) , or a pharmaceutically acceptable salt or solvate thereof, as specifically described in the first aspect of the invention.

In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is a compound (e.g., Compound I, II, III, or IV) as specifically described in the first aspect of the invention, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is Compound 72 or Compound 88.

In some embodiments, the BTK inhibitor is selected from the group consisting of: Ibrutinib, ICP-022, Acalabrutinib (ACP-196) , BGB3111, ONO/GS-4059, Spebrutinib (CC-292 or AVL-292) , CNX-774, Olmutinib (HM61713, BI1482694) , M7583, HM71224, PCI-32765 Racemate, GDC-0853, ONO-4059, Zanubrutinib, RN486, PCI-32765, CGI-1746, QL47, LFM-A13, (±) -Zanubrutinib, SNS-062, BMS-935177, Btk inhibitor 2, Evobrutinib, Ibrutinib-biotin, BMX-IN-1, GDC-0834 and CB1763. Preferably, the BTK inhibitor is selected from the group consisting of: Ibrutinib, Acalabrutinib (ACP-196) and BGB3111. More preferably, the BTK inhibitor is Ibrutinib.

In some embodiments, the medicament is in the form of a pharmaceutical composition.

In some embodiments, the medicament of the invention comprising the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor in the form of a pharmaceutical composition (preferably, each in a separate dosage unit form) , as desired, can be daily administered for, including but not limited to: 1 time, 2 times, 3 times, 4 times, 5 times or 6 times.

In some embodiments, the medicament of the invention comprising the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor in the form of a pharmaceutical composition (preferably, in the form of a dosage unit) , as desired, can be daily administered for, including but not limited to: 1 time, 2 times, 3 times, 4 times, 5 times or 6 times.

In some embodiments, the medicament can be administered in the following manner: oral, buccal, inhalation spray, sublingual, rectal, transdermal, vaginal mucosa, transmucosal, local, nasal or enteral administration; parenteral administration, such as intramuscular injection, subcutaneous injection, intramedullary injection, as well as intrathecal or brain direct administration, in situ administration, subcutaneous, intraperitoneal, intravenous injection, intra-articular synovium, intrasternal, intrahepatic, intralesional, intracranial, intra-abdominal, nasal, or intraocular injection or other drug delivery manners.

In some embodiments, the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor or a pharmaceutically acceptable salt or solvate thereof, and the BTK inhibitor or a pharmaceutically acceptable salt or solvate thereof, are administered in a daily dose as described in the first aspect of the invention in the above detailed description of the invention.

In some embodiments, the disease is cancer. In some embodiments, the cancer is refractory or is resistant to a BTK inhibitor. In certain embodiments, the cancer is refractory or is resistant to ibrutinib.

Further, the cancer described in the present invention includes, but is not limited to, a cancer selected from the group consisting of: adrenal cancer, lymphoid epithelioma, acinic cell carcinoma, lymphoma, acoustic neuroma, acute lymphocytic leukemia, acral lentiginous melanoma, acute myelogeous leukemia, acrospiroma, chronic lymphocytic leukemia, acute eosinophilic leukemia, liver cancer, acute erythroid leukemia, small cell lung cancer, acute lymphoblastic leukemia, non-small cell lung cancer, acute megakaryoblastic leukemia, MALT lymphoma, acute monocytic leukemia, malignant fibrous histiocytoma, acute promyelocytic leukemia, malignant peripheral schwannomas, adenocarcinoma, malignant triton tumor, adenoid cystic carcinoma, mantle cell lymphoma, adenoma, marginal zone B cell lymphoma, adenomatoid odontogenic tumor, mast cell leukemia, adenosquamous carcinoma, mediastinal germ cell tumor, adipose tissue neoplasm, medullary carcinoma of the breast, adrenal cortical carcinoma, medullary thyroid carcinoma, adult T-cell leukemia/lymphoma, medulloblastoma, aggressive NK cell leukemia, melanoma, AIDS-related lymphoma, meningiomas, alveolar rhabdomyosarcoma, merkel cell carcinoma, alveolar soft tissue sarcoma, mesothelioma, ameloblastic fibroma, metastatic urothelial carcinoma, anaplastic large cell lymphoma, mixed mullerian tumor, anaplastic thyroid cancer, mucinous tumor, angioimmunoblastic T-cell lymphoma, multiple myeloma, angiomyolipoma, muscle tissue neoplasm, angiosarcoma, mycosis fungoides, astrocytoma, myxoid liposarcoma, atypical malformation rhabdoid tumor, myxoma, B cell chronic lymphocytic leukemia, myxosarcoma, B-cell prolymphocytic leukemia, nasopharyngeal carcinoma, B-cell lymphoma, neurinoma, basal cell carcinoma, neuroblastoma, biliary tract cancer, neurofibromatosis, bladder cancer, neuroma, blastoma, nodular melanoma, bone cancer, ocular cancer, Brenner tumor, oligodendroglioma, brown tumor, oligodendroglioma, Burkitt's lymphoma, oncocytoma, breast cancer, optic nerve sheath meningioma, brain cancer, optic nerve tumor, carcinoma, oral carcinoma, carcinoma in situ, osteosarcoma, carcinosarcoma, ovarian cancer, cartilage tumor, pancoast tumor, cementoma, papillary thyroid carcinoma, myeloid sarcoma, paraganglioma, chondroma, pinealoblastoma, chordoma, pinealocytoma, choriocarcinoma, pituitary tumor, choroid plexus papilloma, pituitary adenoma, clear-cell sarcoma of the kidney, pituitary tumor, craniopharyngioma, plasmacytoma, cutaneous T-cell lymphoma, polyembryoma, cervical cancer, precursor T lymphoblastic lymphoma, colorectal cancer, primary central nervous system lymphoma, Degos' disease, primary effusion lymphoma, desmoplastic small round cell tumor, primary peritoneal cancer, diffuse large B-cell lymphoma, prostate cancer, dysembryoplastic neuroepithelial tumor, pancreatic cancer, dysgerminoma, pharyngeal carcinoma, embryonal carcinoma, peritoneal pseudomyxoma, endocrine gland tumor, renal cell carcinoma, endodermal sinus tumor, renal medullary carcinoma, enteropathy-associated T-cell lymphoma, retinoblastoma, esophageal cancer, rhabdomyomas, fetus-in-fetus, rhabdomyosarcoma, fibroma, Richter's transformation, fibrosarcoma, rectal cancer, follicular lymphoma, sarcoma, follicular thyroid cancer, schwannomatosis, ganglioneuroma, seminoma, gastrointestinal cancer, sertoli cell tumor, germ cell tumor, sex cord-gonadal stromal tumor, gestational choriocarcinoma, signet ring cell carcinoma, giant cell fibroblastoma, skin cancer, giant cell tumor of bone, small blue round cell tumor, glial tumor, small cell carcinoma, glioblastoma multiforme, soft tissue sarcoma, glioma, somatostatinoma, gliomatosis cerebri, soot wart, glucagonoma, spinal tumor, gonadoblastoma, splenic marginal zone lymphoma, granulosa cell tumor, squamous cell carcinoma, gynandroblastoma, synovial sarcoma, gallbladder carcinoma, Sezary disease, gastric cancer, small intestine cancer, hairy cell leukemia, squamous cell carcinoma, hemangioblastoma, stomach cancer, head and neck cancer, T-cell lymphoma, hemangiopericytoma, testicular cancer, hematological malignancy, hepatoblastoma, thyroid cancer, hepatosplenic T-cell lymphoma, transitional cell carcinoma, Hodgkin's lymphoma, throat cancer, non-Hodgkin's lymphoma, urachal carcinoma, invasive lobular carcinoma, urogenital cancer, intestinal cancer, urothelial carcinoma, kidney cancer, uveal melanoma, laryngeal cancer, uterine cancer, lentigo maligna, verrucous carcinoma, lethal midline carcinoma, visual pathway glioma, leukemia, vulvar cancer, testicular stromal tumor, vaginal cancer, liposarcoma, Waldenstrom's macroglobulinemia (WM) , lung cancer, adenolymphoma, lymphangioma, nephroblastoma and lymphangiosarcoma.

Preferably, the cancer is selected from the group consisting of: acute monocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia and mixed lineage leukemia, NUT midline cancer, multiple myeloma, small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer and breast cancer.

Preferably, the cancer is a hematological malignancy.

More preferably, the hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML) , acute lymphoblastic leukemia (ALL) , diffuse large B-cell lymphoma (DLBCL) , follicular lymphoma (FL) , chronic Lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) , marginal zone lymphoma (MZL) , chronic myelogenous leukemia (CML) , mantle cell lymphoma (MCL) , Waldenstrom's macroglobulinemia (WM) , multiple myeloma (MM) . More preferably, the hematological malignancy is selected from diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) .

Preferably, the cancer is B cell proliferative disease. More preferably, the B cell proliferative disease is selected from the group consisting of: diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell pro-lymphocytic leukemia, lymphoplasmacytic

macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal B-cell lymphoma, lymph node marginal B-cell lymphoma, mantle cell lymphoma, mediastinal (thymus) large B-cell lymphoma, intravascular large B-cell lymphoma, primary exudative lymphoma, Burkitt’s lymphoma /leukemia and lymphomatoid granulomatosis.

In some embodiments, the disease is an autoimmune disease. In some embodiments, the autoimmune disease is refractory or is resistant to a BTK inhibitor. In certain embodiments, the autoimmune disease is refractory or is resistant to ibrutinib.

Further, the autoimmune disease described in the present invention includes, but is not limited to, an autoimmune disease selected from the group consisting of inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease,

syndrome, multiple sclerosis, Guillain-Barré syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture’s syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, familial dysautonomia, endometriosis, interstitial cystitis, neuromyotonia and vulvodynia.

In some embodiments, the disease is an inflammatory disease. In some embodiments, the inflammatory disease is refractory or is resistant to a BTK inhibitor. In certain embodiments, the inflammatory disease is refractory or is resistant to ibrutinib.

Further, the inflammatory disease described in the present invention includes, but is not limited to, an inflammatory disease selected from the group consisting of asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, nasosinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis or vulvitis.

A third aspect of the invention relates to a combination product for preventing and/or treating a disease, in which the combination product comprises a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor, and the disease is selected from the group consisting of cancer, autoimmune disease and inflammatory disease. Further, the cancer, autoimmune disease, and inflammatory disease include, but are not limited to, the cancers, autoimmune diseases and inflammatory diseases described in the second aspect of the invention as described in the above detailed description of the invention. Further, the disease is refractory or is resistant to BTK inhibitors (e.g., ibrutinib) .

In some embodiments, the Bcl-2/Bcl-xL dual inhibitor is a compound (e.g., Compound I, II, III, or IV) as specifically described in the first aspect of the invention, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the Bcl-2/Bcl-xL inhibitor is Compound 72 or Compound 88.

In some embodiments, the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor or a pharmaceutically acceptable salt or solvate thereof, and the BTK inhibitor or a pharmaceutically acceptable salt or solvate thereof, are administered in a daily dose as described in the above first aspect of the invention in the detailed description of the invention.

A fourth aspect of the invention relates to a method of preventing and/or treating a disease, comprising administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor, in which the disease is selected from the group consisting of cancer, autoimmune disease and inflammatory disease. Further, the cancer, autoimmune disease and inflammatory disease include, but are not limited to, the cancers, autoimmune diseases and inflammatory diseases described in the second aspect of the invention in the above detailed description of the invention. Further, the disease is refractory or is resistant to BTK inhibitors (such as ibrutinib) .

In some embodiments, the Bcl-2 inhibitor is a compound (e.g., Compound I-A, Compound I-b, Compound I-c, Compound I-d, Compound I-e, Compound I-f, Compound I-g, Compound I-h, Compound I-i) , or a pharmaceutically acceptable salt or solvate thereof, as specifically described in the first aspect of the invention.

In some embodiments, the medicament is in the form of a pharmaceutical composition, or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are in the form of a pharmaceutical composition.

In some embodiments, the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor in the form of a pharmaceutical composition (preferably, each in a separate dosage unit form) , as desired, can be daily administered for, including but not limited to: 1 time, 2 times, 3 times, 4 times, 5 times or 6 times.

In some embodiments, the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor in the form of a pharmaceutical composition (preferably, in the form of a dosage unit) , as desired, can be daily administered for, including but not limited to: 1 time, 2 times, 3 times, 4 times, 5 times or 6 times.

In some embodiments, the Bcl-2 inhibitor or the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor can be administered in the following manner: oral, buccal, inhalation spray, sublingual, rectal, transdermal, vaginal mucosa, transmucosal, local, nasal or enteral administration; parenteral administration, such as intramuscular injection, subcutaneous injection, intramedullary injection, as well as intrathecal or brain direct administration, in situ administration, subcutaneous, intraperitoneal, intravenous injection, intra-articular synovium, intrasternal, intrahepatic, intralesional, intracranial, intra-abdominal, nasal, or intraocular injection or other drug delivery manners.

In some embodiments, the Bcl-2 inhibitor is administered daily at a dose of 0.017 mg/kg, 0.083 mg/kg, 0.17 mg/kg, 0.33 mg/kg, 0.5 mg/kg, 0.67 mg/kg, 0.83 mg/kg, 1mg/kg, 1.16mg/kg, 1.33mg/kg, 1.5mg/kg, 1.67mg/kg, 2.5mg/kg, 3.33mg/kg, 4.17mg/kg, 5mg/kg, 5.83mg/kg, 6.67mg/kg, 7.5mg/kg, 7.67mg/kg, 7.83mg/kg, 8mg/kg, 8.12mg/kg, 8.16mg/kg, 8.33mg/kg, 9.17mg/kg, 10mg/kg, 10.83mg/kg, 11.66mg/kg, 12.5 mg/kg, 13.33 mg/kg, 14.17 mg/kg, 15 mg/kg, 15.83 mg/kg, 16.67 mg, and a range between the respective application doses, for example, 0.017 mg to 16.67mg/kg, 0.083mg to 16.67mg/kg, 0.17mg to 16.67mg/kg, 0.33mg to 16.67mg/kg, 0.5mg to 15mg/kg, 0.5mg to 13.33mg/kg, 0.5mg to 11.67 mg/kg, 0.5 mg to 10 mg/kg, 0.5 mg to 8.33 mg/kg, 0.5 mg to 8.16 mg/kg, 0.5 mg to 8.12 mg/kg, etc., and the BTK inhibitor administered daily at a dose of 0.17 mg/kg, 0.33 mg/kg, 0.5 mg/kg, 0.67 mg/kg, 0.83 mg/kg, 1 mg/kg, 1.17 mg/kg, 1.22 mg/kg, 1.33 mg/kg, 1.5 mg/kg, 1.62 mg/kg, 1.67mg/kg, 2.03mg/kg, 2.5mg/kg, 3.33mg/kg, 4.17mg/kg, 5mg/kg, 5.83mg/kg, 6.67mg/kg, 7.5 mg/kg, 7.67 mg/kg, 7.83 mg/kg, 8 mg/kg, 8.17 mg/kg, 8.33 mg/kg, and a range between the respective doses, for example, 0.17 mg to 8.33 mg/kg, 0.33 mg to 7.5 mg/kg, 0.5 mg to 6.67 mg/kg, 0.83 mg to 5.83 mg/kg, 1 mg to 5 mg/kg, 1.16 mg to 4.17 mg/kg, 1.22 mg to 3.33 mg/kg, 1.22 mg to 2.5 mg/kg, 1.22mg to 2.03mg/kg, 1.62mg to 8.33mg/kg, 1.62mg to 8mg/kg, 1.62mg to 7.5mg/kg, 1.62mg to 5mg/kg, 1.62mg to 2.5mg/kg, 1.22mg to 1.62mg/kg, etc. In certain embodiments, the Bcl-2/Bcl-xL dual inhibitor is administered daily at a dose of from about 10 mg/week to about 1000 mg/week, from about 10 mg/week to about 900 mg/week, from about 10 mg/week to about 800 mg/week, about 10 mg/week to about 700 mg/week, about 10 mg/week to about 640 mg/week, about 10 mg/week to about 600 mg/week, about 10 mg/week to about 500 mg/week, about 10 mg/week to about 400 mg/week, about 10 mg/week to about 300 mg/week, about 10 mg/week to about 200 mg/week, or about 20 mg/week to about 100 mg/week, for example about 10, 15, 20, 25, 30, 35, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 mg/week.

Lastly, WO 2018/027097 is incorporated by reference herein, in its entirety and for all purposes.

Specific Models for Carrying Out the Invention

The present invention will be further illustrated by the following examples and control examples. However, it should be understood that these examples and control examples are merely used to explain the invention in more details, but not intend to limit the present invention.

Example 1. General experimental methods used in the invention

(1) WST experiment

The anti-proliferative effect was tested by CCK-8 (Cell Counting Kit-8) (purchased from Shanghai Liji Medical Technology Co., Ltd. ) based on water-soluble tetrazolium salt (WST) (please refer to: Ishiyama M, Tominaga H, Shiga M et al., A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharm. Bull 19 (11) 1518-1520 (1996) , Vol. 19, No. 11; and Tominaga H, Ishiyama M, Ohseto F et al., A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal. Commun., 1999, 36, 47-50) . Cells were inoculated to 96-well plates, treated with different concentrations of the test substance for 72 hours. By acting 9 different concentrations of BTK inhibitor (for example, Ibrutinib, wherein 9 concentrations were selected in a 3×gradient between 10 ^-2 and 10 ²) with 3 different concentrations of Compound 6 (see Figure 1 for details) for 72 hours, the combination effect of Compound 6 and the drug were tested. Each test dose was tested with 3 replicate wells.

Usually, 9 series of doses of the test substance were selected, and added to 96-well plates, 100 μl/well. For the combination experiment, the final volume of the two test substances is 100 μl/well. Each test dose was tested with 3 replicate wells. On the same plate, 3-6 wells were selected and added with 100 μl of dilution solution as a control group, and another 3-6 wells were used as a blank control. In addition to the blank control wells, 100 μl of the cell suspension was added to each well (containing an appropriate number of cells to ensure that at the time of detection, the cells of the cell control group just covered the bottom of the well) of the same 96-well plate. The culture plate was cultured at 37℃ for 72 hours in a CO ₂ incubator. At the end of the culture, for the adherent cells, the old solution in the well to be tested was removed, and 100 μl/well of CCK-8 test solution (corresponding medium containing 10%CCK-8, 5%FBS) was added. For the suspension cells, 20 μl/well of CCK-8 stock solution was added directly. The plate was continuously incubated at 37℃ for 2-4 h in CO ₂ incubator.

The OD values were measured at A450nm by a microplate reader (SpectraMax Plus 384, Molecular Devices, LLC., US) . Using the average OD value of 3 replicate wells, the percentage of cell viability was calculated by the following formula:

(O.D. of test well –O.D. of blank control well) / (O.D. of cell control well -O.D. of blank control well) × 100.

The IC ₅₀ was calculated using the nonlinear regression data analysis method of Graphpad Prism 6.0 software.

For the combination test, the cell survival rate was calculated by normalizing the average OD value of 3 duplicate wells of the single drug control. By comparing the IC ₅₀ of the combination curve with the single drug curve, the synergistic effect of two compounds was determined by combining the observation of whether the curve of the combination group was shifted left.

(2) Evaluation method of in vivo pharmacodynamics experimental

A subcutaneous xenograft tumor model of human tumor immunodeficient mice was established by cell inoculation: tumor cells in logarithmic growth phase were collected, counted and resuspended in 1×PBS, and the cell suspension concentration was adjusted to 2.5-5×10 ⁷/mL. Using a 1 mL syringe (4th needle) , the tumor cells were inoculated subcutaneously in the right side of immunodeficient mice, 5-10×10 ⁶/0.2 mL/mouse. All animal experiments were strictly in accordance with the laboratory animal use and management practices of GenePharma Co., Ltd. and Ascentage Pharma Group Co., Ltd. The calculation of relevant parameters referred to the Chinese CFDA "Guidelines for Non-Clinical Research Techniques of Cytotoxic Antitumor Drugs" . The sources of experimental animals are shown in the following table:

Table 2: Experimental animal sources

Animal body weight and tumor size were measured twice a week during the experiment. Tumor growth was observed periodically, and the animals were randomly divided into groups according to tumor size and mouse body weight when the tumors grew to an average volume of 100-200 mm ³. The conditions and death of the animals were observed every day. Routine monitoring included the effects of tumor growth and treatment on normal animal behaviors, including activity, feeding and drinking situations, weight gain or loss, eyes, coat and other abnormalities in the experimental animals. The deaths and clinical symptoms observed during the experiment were recorded in the raw data. The entire operations of administration, measurement of mouse body weight and tumor volume were performed in a clean bench. Plasma and tumor tissues were collected, weighed and photographed after the end of the last administration according to the experimental protocol. Plasma and tumor samples were frozen and stored at -80℃.

Tumor volume (TV) was calculated as: TV = a×b ²/2, in which a and b represented the length and width of the tumor as measured, respectively. The relative tumor volume (RTV) was calculated as: RTV=V _t/V ₁, in which V ₁ was the tumor volume at the time of grouping and administration, and V _t was the tumor volume measured on a day after administration. The evaluation index of anti-tumor activity was the relative tumor proliferation rate T/C (%) , which was calculated as: relative tumor proliferation rate T/C (%) = (T _RTV /C _RTV) × 100%, in which T _RTV was the RTV of the treatment group, C _RTV was the RTV of the vehicle control group; tumor remission rate (%) was calculated as: (the number of SD (stable disease) , PR (tumor partial regression) and CR (tumor complete regression) in the tumor-bearing mice after treatment) /the total number of mice in the group × 100%.

Change of body weight %= (measured body weight -body weight at the time of grouping) /body weight at the time of grouping × 100%.

Evaluation criteria of therapeutic efficiency: according to the Chinese CFDA "Technical guidelines for non-clinical research on cytotoxic antitumor drugs" (November 2006) , it was determined as effective when the T/C (%) value was ≤40%and statistic analysis showed p < 0.05; and a dose of the drug was considered to be severely toxic when the body weight of the mice dropped by more than 20%or the rate of drug-related deaths exceeded 20%.

The synergistic analysis was performed by the following formula: synergy factor = ( (A/C) × (B /C) ) / (AB /C) ; A = RTV value of the group administered with A only; B = RTV value of the group administered with B only; C = RTV value of the vehicle control group; AB = RTV value of the group administered with A and B in combination (Clarke R. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models [J] . Breast Cancer Research & Treatment, 1997, 46 (2-3) : 255-278) . If the synergy factor was >1, there was a synergistic effect; if the synergistic factor = 1, there was an additive effect; if the synergistic factor < 1, there was an antagonistic effect.

Example 2. Preparation of exemplary compounds as Bcl-2 inhibitors (

Compounds

3, 6 and 13)

(1) Synthesis of 2- ( (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy) -4- (4- ( (6- (4-chlorophenyl) spiro [3.5] non-6-en-7-yl) methyl) piperazin-1-yl) -N- ( (3-nitro-4- ( ( (tetrahydro-2H-pyran-4-yl) methyl) amino) phenyl) sulfonyl) benzamide (Compound 3)

A mixture of 2- ( (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy) -4- (4- ( (6- (4-chlorophenyl) spiro [3.5] non-6-en-7-yl) methyl) piperazin-1-yl) benzoic acid (1.75 g, 3 mmol) , 3-nitro-4- ( ( (tetrahydro-2H-pyran-4-yl) methyl) amino) benzenesulfonamide (1.43 g, 4.5) reacted in EDCI (1.15 g, 6 mmol) and 4- (N, N-dimethylamino) pyridine (550 mg, 4.5 mmol) and dichloromethane (40 ml) at room temperature overnight, and then water was added. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, concentrated and purified with silica column to obtain 2- ( (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxo) -4- (4- ( (6- (4-chlorophenyl) spiro [3.5] non-6-en-7-yl) methyl) piperazin-1-yl) -N- ( (3-nitro-4- ( (tetrahydro-2H-pyran-4-yl) methyl) amino) phenyl) sulfonyl) benzamide (1.7 g, 64.4%) was obtained as a yellow solid.

¹H NMR (400 MHz, methanol-d4) δ 8.70 (d, J = 2.3 Hz, 1H) , 8.01 (d, J = 2.7 Hz, 1H) , 7.87 (d, J = 9.2, 2.3 Hz, 1H) , 7.66 (d, J = 8.9 Hz, 1H) , 7.55 (d, J = 2.7 Hz, 1H) , 7.47 (d, J = 3.4 Hz, 1H) , 7.38 (d, J = 8.4 Hz, 2H) , 7.10 (d, J =8.4 Hz, 2H) , 6.97 (d, J = 9.2 Hz, 1H) , 6.77 (dd, J = 8.9, 2.4 Hz, 1H) , 6.44 (d, J = 3.4Hz, 1H) , 6.34 (d, J = 2.4 Hz, 1H) , 4.02 –3.94 (m, 3H) , 3.66 (s, 3H) , 3.49 –3.38 (m, 2H) , 3.41 –3.25 (m, 7H) , 2.42 (s, 3H) , 2.26 (s, 3H) , 2.00 –1.67 (m, 4H) , 1.45 –1.38 (m, 2H) .

(2) Synthesis of (R) -N- ( (4- ( ( (1, 4-dioxan-2-yl) methyl) amino) -3-nitrophenyl) sulfonyl) -2- ( (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy) -4- (4- ( (6- (4-chlorophenyl) spiro [3.5] non-6-en-7-yl) ) methyl) piperazin-1-yl) benzamide (Compound 13)

The title compound was prepared in a similar manner to that described for the synthesis of Compound 3.

¹H NMR (400 MHz, methanol-d4) δ 8.66 (d, J = 2.4 Hz, 1H) , 7.99 (d, J = 2.4 Hz, 1H) , 7.84 (dd, J = 9.2, 2.4 Hz, 1H) , 7.64 (d, J = 8.9 Hz, 1H) , 7.51 (d, J = 2.4 Hz, 2H) , 7.45 (d, J = 3.3 Hz, 1H) , 7.37 (d, J = 8.4 Hz, 2H) , 7.10 (d, J =8.4 Hz, 2H) , 6.94 (d, J = 9.2 Hz, 1H) , 6.76 (dd, J = 8.9, 2.3 Hz, 1H) , 6.40 (d, J = 3.3Hz, 1H) , 6.36 (d, J = 2.3 Hz, 1H) , 3.87 (dd, J = 11.8, 4.2 Hz, 3H) , 3.83 –3.70 (m, 3H) , 3.67 (s, 2H) , 3.62 (dd, J = 11.7, 2.9 Hz, 1H) , 3.51 –3.41 (m, 2H) , 3.40 –3.35 (m, 1H) , 3.29 (dq, J = 3.2, 1.6 Hz, 1H) , 2.41 (s, 2H) , 2.26 (s, 2H) , 2.00 –1.77 (m, 6H) .

Similarly, Compound 6 was prepared similarly according to the method described for the synthesis of Compound 13, with specific reference to WO 2018/027097.

Example 3. Effects of Ibrutinib alone and combination of Ibrutinib and Compound 6 on different malignant tumor cells

(1) The experimental method was as described in Example 1 (1) . The cell viability (%) of Ibrutinib alone and the combination of Ibrutinib and Compound 6 in the following malignant tumor cells were determined in WST experiments: OCI-LY8 (diffuse large B-cell lymphoma (DLBCL) ) , SU-DHL-4 (diffuse large B-cell lymphoma (DLBCL) ) , OCI-LY1 (diffuse large B-cell lymphoma (DLBCL) ) , DOHH2 (follicular lymphoma (FL) ) , RPMI-8226 (multiple myeloma (MM) ) , KMS-11 (multiple myeloma (MM) ) , Z-138 (mantle cell lymphoma (MCL) ) .

(2) Experimental results

As shown in Figure 1, in a variety of hematological malignant cells, the combination of Compound 6 and BTK inhibitor Ibrutinib showed increased inhibition effects on the proliferation of the tumor cells.

Specifically, in OCI-LY8 (DLBCL) , the IC ₅₀ of Ibrutinib alone for inhibition of proliferation was 21.78, while the IC ₅₀ values of Ibrutinib and Compound 6 (0.1 μM, 0.3 μM, 0.6 μM) for inhibition of proliferation were 10.88, 6.06, and 3.00, respectively; in SU-DHL-4 (DLBCL) , the IC ₅₀ of Ibrutinib alone for inhibition of proliferation was 2.343, while the IC ₅₀ values of Ibrutinib and Compound 6 (0.4 μM, 1.2 μM, 3.6 μM) for inhibition of proliferation were 0.14, 0.084, and 0.066, respectively; in OCI-LY1 (DLBCL) , the IC ₅₀ of Ibrutinib alone for inhibition of proliferation was 0.132, while the IC ₅₀ values of Ibrutinib and Compound 6 (0.01 μM, 0.02 μM, 0.03 μM) for inhibition of proliferation were 0.019, 0.007, and 0.002, respectively; in DOHH2 (FL) , the IC ₅₀ of Ibrutinib alone for inhibition of proliferation was 0.021, while the IC ₅₀ values of Ibrutinib and Compound 6 (0.001 μM, 0.005 μM, 0.02 μM) for inhibition of proliferation were 5.967×10 ^-4, 2.162×10 ^-4, and 4.957×10 ^-4, respectively; in RPMI-8226 (MM) , the IC ₅₀ of the proliferation of Ibrutinib alone for inhibition of proliferation was 18.69, while the IC ₅₀ values of Ibrutinib and Compound 6 (3 μM, 6 μM, 9 μM) for inhibition of proliferation were 4.397, 3.217 and 3.63, respectively; in KMS-11 (MM) , the IC ₅₀ of Ibrutinib alone for inhibition of proliferation was 14.85, while the IC ₅₀ values of Ibrutinib and Compound 6 (1 μM, 2.5 μM, 5 μM) for inhibition of proliferation were 9.062, 7.203 and 7.227, respectively; in Z-138 (MCL) , the IC ₅₀ of Ibrutinib for inhibition of proliferation was 10.6, while the IC ₅₀ values of Ibrutinib and Compound 6 (4μM, 6μM, 10μM) for inhibition of proliferation were 3.371, 3.531 and 1.663, respectively.

(3) Summary

Thus, in vitro experiments, when Compound 6 was used in combination with a targeting therapeutic drug (i.e, a BTK inhibitor) , the in vitro anti-proliferative activity of Compound 6 in hematological malignancies was further enhanced. The comparison of IC ₅₀ was performed with the curves of combination administration and the curves of single administration, and it was observed that the curves of combination administration showed left shift, and the IC ₅₀ values of the combination administration groups were smaller than the IC ₅₀ values of respective single administration. Therefore, the combination of Ibrutinib and Compound 6 had a synergistic effect.

Example 4. Effects of Ibrutinib alone and combination of Ibrutinib and Compound 6 in human OCI-LY1 cell line DLBCL mouse xenograft tumor model

(1) The experimental method was as described in the section (2) of Example 1. In the experiment, the therapeutic effects of the combination of Ibrutinib and Compound 6 were evaluated with a DLBCL xenograft tumor model derived from a human OCI-LY1 cell line (see: Donnou S, Galand C, Touitou V et al., Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies. Advances in Hematology, Volume 2012, Article ID 701704, 13 pages; and, Benet Pera, Tiffany Tang, Rossella Marullo et al., Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenetics 2016; 8: 79) . In short, when the average tumor volume reached approximately 90 mm ³, grouping and administration started. Ibrutinib was administered at a dose of 15 mg/kg, i.v., qd, from the day of grouping, for 3 weeks. Compound 6 was administered at a dose of 100 mg/kg, p.o., qd, from the 8 ^th day after grouping, for 3 weeks. In addition, the group of combination of Ibrutinib and Compound 6 (Ibrutinib 15 mg/kg, i.v., qd + Compound 6 100 mg/kg, p.o., qd) was also provided.

(2) Experimental results

Due to the slow growth of tumor in this model, the initial effect was not obvious. On the 13 ^th day after grouping, the administration was stopped and the observation period started.

On day 43 after grouping, the Compound 6 group showed good tumor growth inhibition with a T/C%value of 4% (P<0.001; including 1/5 CR and 1/5 PR, and remission rate was 20%) (Figure 2A and Table 3) . Ibrutinib showed limited effect in this model, with a T/C%value of 58% (P>0.05) . The combination of drugs significantly enhanced the efficacy, showing a T/C%value of 0% (P<0.001, compared with the vehicle control; including 4/5 CR and 1/5 PR, and the remission rate was 100%) ; although the RTV value was not statistically different from that of the Compound 6 alone group (P>0.05) , it showed statistically difference compared with the Ibrutinib alone group (P<0.05) . At the same time, 4/5 CR appeared in the combination group, suggesting that the combination was superior to the drug alone. With the prolongation of time, the difference between the combination group and the Compound 6 alone group became more and more obvious. On the 50 ^th day, the effect of the combination group was better than that of the two drug alone groups (P<0.05, compared with the Compound 6 alone group; P<0.01, compared with the Ibrutinib alone group) . On the 68 ^th day, the RTV value of the combination group was still smaller than that of the Compound 6 alone group (P<0.05) , and there were still 2/5 CR and 2/5 PR. No significant weight loss was observed in each of the drug-administered groups (Figure 2B) .

Table 3. Anti-tumor effects of Compound 6 alone or in combination with Ibrutinib in human OCI-LY1 (DLBCL) mouse xenograft tumor model

(3) Summary

The combination of Compound 6 and Ibrutinib had no significant side effects, significantly increased the anti-tumor effect of single drug in the DLBCL model of OCI-LY1 cells, and showed a significant synergistic effect (synergistic factor was 8.59, much larger than 1) . Therefore, the combination of Compound 6 and Ibrutinib may clinically benefit patients with diffuse large B-cell lymphoma (DLBCL) .

Example 5: Effects of Ibrutinib alone and combination of Ibrutinib and Compound 6 in human DOHH2 cell line FL mouse xenograft tumor model

(1) The experimental method was as described in the section (2) of Example 1. In the in vitro cell assay, DOHH2 was a human follicular lymphoma (FL, belonging to NHL) cell line that was relatively sensitive to Compound 6 treatment. Therefore, in the experiment, a FL mouse xenograft tumor model derived from DOHH2 cells was established (see: Donnou S, Galand C, Touitou V et al., Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies. Advances in Hematology, Volume 2012, Article ID 701704, 13 pages; and, Ackler S, Mitten MJ, Chen J et al., Navitoclax (ABT-263) and bendamustine ±rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. British Journal of Pharmacology (2012) 167 881-891) , which was used to evaluate the anti-tumor effect of Compound 6 in combination with BTK inhibitor Ibrutinib.

(2) Experimental results

As shown in Figure 3A and Table 4, the T/C value of the Ibrutinib (25 mg/kg) treatment group was 48%after 32 days of treatment. The T/C values of the Compound 6 (100 mg/kg) alone group and the combination group with Ibrutinib were 19% (P<0.01, compared with the vehicle control group) and 8% (P<0.001, compared with the vehicle control group; P<0.001, compared with the Compound 6 alone group; P <0.01, compared with the Ibrutinib alone group) , respectively.

Table 4. Anti-tumor effects of Compound 6 alone or in combination with Ibrutinib in human DOHH2 (FL) mouse xenograft tumor model

(3) Summary

The combination of Compound 6 and Ibrutinib had no significant side effects (Figure 3B) , significantly increased the anti-tumor effect of single drug in human DOHH2 (FL) mouse xenograft tumor model, and had significant synergistic effect (synergistic factor was 1.21, greater than 1) . Therefore, the combination of Compound 6 and Ibrutinib may clinically benefit patients with follicular lymphoma (FL) .

Example 6: Effects of Ibrutinib alone and combination of Ibrutinib and Compound 6 in human DOHH2 cell line FL mouse xenograft tumor model

(1) The experimental method was as described in the section (2) of Example 1. In the experiment, a FL mouse xenograft tumor model derived from DOHH2 cells (same as in Example 5) was established, and the anti-tumor effect of the combination of Compound 6 and BTK inhibitor Ibrutinib was evaluated.

(2) Experimental results

As shown in Figure 4A and Table 5, after 35 days of treatment, the T/C value of the Ibrutinib (20 mg/kg) treatment group was 67.7% (no significant difference compared with the vehicle control group) . The T/C values the Compound 6 (50 mg /kg) alone and the combination with Ibrutinib were 44.40% (P<0.001, compared with the vehicle control group) and 21.8% (P<0.001, compared with the vehicle control group; P<0.01, compared with the Compound 6 alone group; P<0.05, compared with the Ibrutinib alone group) .

Table 5. Anti-tumor effects of Compound 6 alone or in combination with Ibrutinib in human DOHH2 (FL) mouse xenograft tumor model

(3) Summary

The combination of Compound 6 and Ibrutinib had no significant side effects (4B) , significantly increased the anti-tumor effect of single drug in human DOHH2 (FL) mouse xenograft tumor model, and had a significant synergistic effect (synergistic factor of 1.3, more than 1) . Therefore, the combination of Compound 6 and Ibrutinib may clinically benefit patients with follicular lymphoma (FL) .

Example 7. Effects of Ibrutinib alone and combination of Ibrutinib and Compound 6 on human OCI-LY1 cell line DLBCL mouse xenograft tumor model

(1) The experimental method was as described in section (2) of Example 1. In the experiment, the therapeutic effect of the combination of Compound 6 and Ibrutinib in a DLBCL xenograft tumor model derived from the human OCI-LY1 cell line (same as Example 4) was evaluated.

(2) Experimental results

As shown in Figure 5A and Table 6, on the 36th day after grouping, the combination group had a significant difference in RTV values relative to the Ibrutinib alone group.

Table 6. Anti-tumor effects of Compound 6 alone or in combination with Ibrutinib in human OCI-LY1 (DLBCL) mouse xenograft tumor model

(3) Summary

The combination of Compound 6 and Ibrutinib had no significant side effects (Figure 5B) , significantly increased the anti-tumor effect of single drug in the DLBCL model of OCI-LY1 cells, and had a significant synergistic effect (synergy factor was 1.26, greater than 1) . Therefore, the combination of Compound 6 and Ibrutinib may clinically benefit patients with diffuse large B-cell lymphoma (DLBCL) .

Example 8. The inhibition effect of Ibrutinib or Compound 6 alone and combination of Ibrutinib and Compound 6 on cell growth in DLBCL and follicular lymphoma cells.

(1) Materials and methods

Reagents

Ibrutinib was purchased from Selleck (China, Cat. S2680) or Aikonchem (Nanjing, China, Cat. 2645743) . For in vivo studies, ibrutinib (Selleck) was formulated in 10%PEG400 (Sigma, St. Louis, MO, Cat. 91893-1L-F) , 5%Cremophor EL (Sigma, Cat. C5135-500G) and 85%PBS (GENOME, Hangzhou, China, Cat. GNM14190) ; whereas ibrutinib (Aikonchem) was formulated in 5%DMSO (Sigma, Cat. D8418) plus 95% (20%H-β-CD) (Seebio, Shanghai, China, Cat. ACJ0024A) . For in vitro studies, ibrutinib was dissolved in DMSO to 10 mM stock solution and diluted in serum-free medium to indicated concentration. Compound 6 (R16JA450041-A5s) was synthesized by Ascentage Pharma (Suzhou, China) . ABT-199 was purchased from Aikonchem (Naijing, China, Cat. 2427965) . Compound 6 and ABT-199 were formulated in 10%ethanol (Sinopharma, Shanghai, China, Cat. 10009257) , 30

%polyethylene glycol

400 and 60%Phosal 50 PG (Lipoid GmbH, Germany, Cat. 368315-31700201006) for in vivo studies. Compound 6 used in vitro was dissolved in DMSO to 10 mM stock solution and diluted to indicated concentration with serum-free medium. Antibodies used in this study were purchased from Cell Signaling Technology (CST, China) : AKT (Cat. 4685S) , p-AKT (Ser473) (Cat. 4060S) , BAX (Cat. 5023) , Bcl-2 (Cat. 4223) , BIM (Cat. 2819S) , BTK (Cat. 8547S) , p-BTK (Tyr223) (Cat. 5082S) , caspase-2 (Cat. 9665S) , MCL-1 (Cat. 94296S) , PARP-1 (Cat. 9532) , β-ACTIN (Cat. 3700S) .

Cell lines

The human B cell lymphoma cell line DOHH-2 was provided by Dr. Shaomeng Wang (University of Michigan, Ann Arbor, MI) . The human diffused large-B-cell lymphoma cell line OCI-LY1 was obtained from Dr. Dajun Yang (Sun Yat-Sen University Cancer Center, Guangdong, China) . All cell lines were tested and authenticated by STR (short-tandem repeat) analysis. DOHH-2 cells were cultured in RPMI 1640 medium (GIBCO, China, Cat. C11875500BT) supplemented with 10%fetal bovine serum (GIBCO, Australia, Cat. 10099-141) and 1%Penicillin/Streptomycin (GENOME, Hangzhou, China, Cat. GNM15140) . OCI-LY1 cells were cultured in IMDM (GIBCO, China, Cat. 12200036) medium containing 20%fetal bovine serum and 1% Penicillin/Streptomycin. Cells were cultured and maintained at 37℃ in a humidified incubator with 5%CO ₂ and 95%air.

Cell viability assays

Cell viability was determined by using

luminescent cell viability assay (Promega, China) according to manufacturer’s instruction. Briefly, 5000 cells were seeded in 96-well plates and treated with single agent or drug combinations for 72 h.

reagent was added into the 96-well plates (30 μL/well) after drug treatment and incubated with cells for 15 minutes. Relative light unit (RLU) were determined by microplate reader (BioTek, Synergy H1 MF, USA) . Cell viability was calculated as cell viability = (mean RLU sample –mean RLU blank) / (RLU cell control -RLU blank) × 100. IC ₅₀ value was calculated using GraphPad Prism. IC ₅₀ was expressed as mean ± standard deviation (SD) . Combination index (CI) value was calculated by CalcuSyn software (BIOSOFT, UK) . In general, synergy scores>1, CI < 0.9 indicate a synergistic combination effect. CI<0.1 labeled as 5+ indicates very strong synergistic combination effect, CI between 0.1 and 0.3 labeled as 4+indicates strong synergistic combination effect, CI between 0.3 and 0.7 labeled as 3+ indicates medium synergistic combination effect.

(2) Experimental results

High level of BCL2 expression was documented correlating with poor prognosis in B-lymphocyte neoplasm. Indeed, BCL2 is upregulated in ibrutinib-resistant cell lines and these cells are sensitive to Bcl-2 inhibitor ABT-199 and its combination with BTK inhibitor ibrutinib (Kuo et al., 2017) . Compound 6 is a novel, orally bioavailable BH3-mimetic that selectively inhibits BCL-2, but not BCL-xL or MCL-1. Anti-proliferative activities of Compound 6 as a single agent is comparable if not better than ABT-199 in various hematological malignancies cell lines including those from DLBCL and FL (data not shown) . Here, we evaluated whether combination treatment with Compound 6 and ibrutinib could further enhance the anti-proliferative activities in these hematological malignancies cell lines.

In the experiment, proliferation of FL (Fig 6A) and DLBCL (Fig 6B) cells was assessed by

cell viability assay 72 hours after the treatments with Compound 6, ibrutinib, or the combination of both agents at indicated concentrations. Dose-response curves for cell viability (Fig 6A left and Fig 6B left) and drug dose matrix (Fig 6A right and Fig 6B right) are shown. The CI values of the combination treatment with Compound 6 and ibrutinib at indicated concentration were calculated by CalcuSyn (BIOSOFT) . CI<0.9 indicates a synergistic effect of two agents. Drug dose matrix indicates percentage of growth inhibition of treated cells relative to the vehicle control group.

Specifically, cell viability tests from human FL DOHH-2 (Fig 6A) and DLBCL OCI-LY1 (Fig 6B) cells revealed that the dose response curve of Compound 6 combined with ibrutinib shifted toward left compared to single agents alone, suggesting synergistic effects. Combination index (CI) of Compound 6 and ibrutinib was calculated for different dosages of combination as indicated (Fig 6A left and Fig 6B left) . In DOHH2 cell lines, synergy and CI was recorded from low concentration of Compound 6 (0.41 nM) and ibrutinib (1.4 nM) onwards. While in OCI-LY1 cell lines, synergy and CI was exhibited at higher concentration of Compound 6 (33 nM) and ibrutinib (1111 nM) onwards. Percentage of growth suppression for each concentration of combination in DOHH2 and OCI-LY1 was obtained and plot as drug dose matrix are shown in Fig 6A right and Figure 6B right. Figure 6 shows that Ibrutinib synergizes with Compound 6 on inhibition of cell growth in DLBCL and follicular lymphoma cells.

Example 9. The effect of Ibrutinib or Compound 6 alone and combination of Ibrutinib and Compound 6 on the apoptosis of FL and DLBCL cell lines.

(1) Materials and methods

The reagents and cell lines were as described in the section (1) of Example 8.

Flow cytometry analysis of cell apoptosis

Apoptosis was evaluated with AnnexinV/propidium iodide (PI) dyes (BD Biosciences, Cat. 556547) according to manufacturer’s instructions. Briefly, cells were seeded in 24-well plates at a density 2 × 10 ⁵ cells/well, and treated with Compound 6 and/or ibrutinib (Selleck) to induce apoptosis. After 24h, cells were collected, washed twice with PBS (pH 7.4) , and stained with Annexin-V and propidium iodide (PI) for 15 mins. Stained samples were analyzed using flow cytometer Attune NxT (Life technologies) .

(2) Experimental results

Although ibrutinib is currently in routine clinical practice for treating CLL patients, apoptosis induced by ibrutinib has been documented as limited (Cinar et al., 2013; Deng et al., 2017) . We hypothesized that by targeting distinct survival pathways using inhibitors of BTK and BCL may enhance rate of apoptosis and contribute to the synergistic anti-proliferation.

In the experiment, the combination treatment with Compound 6 and ibrutinib was evaluated for its ability of apoptosis induction on DOHH2 and OCI-LY1 cells by co-staining of Annexin-V/Propidium iodide (PI) followed by flow cytometry analysis (Fig 7A) . When cells were treated with ibrutinib alone, limited apoptosis activity was observed, consistent with previous reported studies (Deng et al., 2017) . Compound 6 treated cells, showed slightly enhanced apoptotic activity. Notably, combined treatment of Compound 6 and ibrutinib resulted in increased cellular apoptosis with statistical significance (p < 0.001) (Fig 7B) . Flow cytometry analysis of apoptotic cells by Annexin V and propidium iodide (PI) co-staining in DOHH-2 and OCI-LY1 cell lines treated with 10 nM (DOHH-2) or 15 nM (OCI-LY1)

Compound

6, 100 nM (DOHH-2) or 150 nM (OCI-LY1) ibrutinib, or the combination for 24 hours. Three independent experiments were conducted and the representative results are shown (7A) . The percentages of Annexin V-positive, PI-positive, or double positive DOHH-2 (7B) and OCI-LY1 (7C) cells are plotted as bar charts and shown as mean ± SEM (n=3) (**p<0.01, ***p<0.001) . Figure 7 shows that the synergistic induction of apoptosis of FL and DLBCL cells by combination treatment with Compound 6 and ibrutinib in vitro.

Example 10. Synthesis of Bcl-2/Bcl-xL dual inhibitors

Compound 72: (R) -2- (1- (3- (4- (N- (4- (4- (3- (2- (4-chlorophenyl) ) -1-isopropyl-5-methyl-4- (methylsulfonyl) -1H-pyrrol-3-yl) -5-fluorophenyl) piperazin-1-yl) phenyl) sulfamoyl) -2- (trifluoromethylsulfonyl) phenylamino) -4- (phenylthio) butyl) piperidine-4-carbonyloxy) ethylphosphonic acid. Compound 72 can be prepared by the following method, as described in the specification of WO2014/113413A1.

1H NMR (300 MHz, CD3OD) : δ7.93 (d, J=1.9 Hz, 1H) , 7.72 (dd, J=9.2, 1.8Hz, 1H) , 7.30-7.12 (m, 12H) , 6.83-6.42 (m, 5H) , 4.46-4.33 (m, 3H) , 3.96 (s, 1H) , 3.54-2.93 (m, 16H) , 2.82 (s, 3H) , 2.72 (s, 3H) , 2.71-2.55 (m, 1H) , 2.24-1.65 (m, 8H) , 1.41 (d, J = 7.1 Hz, 6H) . MS (ESI) : m/z 1268.58 (M+H) ⁺.

Compound 88: (R) -1- (3- (4- (N- (4- (4- (3- (2- (4-chlorophenyl) -1-isopropyl-5-methyl-4- (methylsulfonyl) -1H-pyrrol-3-yl) -5-fluorophenyl) piperazin-1-yl) phenyl) -sulfamoyl) -2- (trifluoromethylsulfonyl) phenylamino) -4- (phenylthio) butyl) piperidine-4-carboxylic acid. Compound 88 can be prepared by the following method, as described in the specification of WO2014/113413A1.

1H NMR (400 MHz, DMSO-d6) δ 9.84 (s, 1H) , 7.82 (s, 1H) , 7.65 (d, J = 8.7 Hz, 1H) , 7.38 (d, J = 8.5 Hz, 2H) , 7.32 –7.14 (m, 7H) , 7.11 –6.81 (m, 6H) , 6.63 –6.47 (m, 2H) , 6.43 –6.30 (m, 1H) , 4.33 (p, J = 7.1 Hz, 1H) , 4.07 (s, 1H) , 3.32-3.22 (m, 4H) , 3.19 –3.03 (m, 9H) , 2.89 (s, 4H) , 2.67 (s, 4H) , 2.31-1.55 (m,8H) , 1.35 (d, J = 7.0 Hz, 6H) .

Example 11. Establishment of Ibrutinib-resistant DOHH2R cell line

DOHH2 is a human follicular lymphoma (FL, belonging to the NHL) cell line provided by Dr. Shaomeng Wang (University of Michigan, Ann Arbor, MI) . DOHH2 cells were cultured in RPMI1640 medium containing 10%calf serum, 1%antibiotics and 5 ug/ml verapamil (calcium ion channel blocker) , and ibrutinib was added at a gradually increasing concentration from 0.5 uM to 10 uM. After exposure for about three months, a ibrutinib-resistant DOHH2R cell line was obtained, also referred to as DOHH2 ^R-ibrutinib. After DOHH2 ^R-ibrutinib was stabilized, it was continued to be cultured in culture medium containing 10 uM Ibrutinib to maintain its resistance. Ibrutinib is absent only in the susceptibility test with

Compound

6 or 88.

Cell viability assays

Cell viability was determined by using the

luminescent cell viability assay (Promega, China) according to manufacturer's instruction. Briefly, 5000 DOHH2 ^R-ibrutinib cells were seeded in 96-well plates and treated with test drugs for 24 or 72 hours. CellTiter-Glo reagent was added into the 96-well plates (30 μL/well) after drug treatment and incubated with the cells for 15 minutes. Relative light units (RLU) were determined by a microplate reader (BioTek, Synergy H1MF, USA) . Cell viability was calculated as cell viability = (mean RLU sample -mean RLU blank) / (RLU cell control -RLU blank) x 100. IC ₅₀ values were calculated using GraphPad Prism. IC ₅₀ was expressed as mean ± standard deviation (SD) .

The cell viability assay of ibrutinib showed that the IC ₅₀ value of ibrutinib to DOHH2 cells was 0.07352 μM, but the IC ₅₀ value of ibrutinib to the DOHH2 ^R-ibrutinib cell line was 12.19 μM, which was a 160-fold increase (Fig. 8) , indicating that DOHH2 ^R-ibrutinib cells were resistant to ibrutinib.

The effect of BCL-2 inhibitors on cell viability was tested in DOHH2 cells and Ibrutinib-resistant DOHH2 ^R-ibrutinib cells, respectively. Two BCL-2 inhibitors, Compound 6 and ABT-199, were compared. The results showed (Fig. 9) that both Compound 6 and ABT-199 were both effective in inhibiting the growth of DOHH2 cells and showed similar IC ₅₀ values (0.0484 μM for Compound 6, and 0.0511 μM for ABT-199) , but Compound 6 showed significantly higher inhibitory effect on the growth of DOHH2 ^R-ibrutinib cells than ABT-199, indicating that Compound 6 can better overcome the resistance of the DOHH2 ^R-ibrutinib cell line to ibrutinib. The IC ₅₀ value of Compound 6 to the DOHH2 ^R-ibrutinib cell line was 0.648 μM, while the IC ₅₀ value of ABT-199 to the DOHH2 ^R-ibrutinib cell line was 1.189 μM, which was significantly inferior to the effect of Compound 6.

The effect of BCL-2/BCL-xL dual inhibitor Compound 88 on cell viability was further tested in DOHH2 cells and ibrutinib-resistant DOHH2 ^R-ibrutinib cells, respectively. The results showed that Compound 88 potently inhibited the growth of ibrutinib-resistant DOHH2 ^R-ibrutinib cells with an IC ₅₀ value of 0.017 μM, and led to cell death within 24 hours.

Claims

A combination product comprising a Bcl-2 inhibitor and a BTK inhibitor, or comprising a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor.
A method for treating a disease in a subject in need thereof, comprising administering a therapeutically effective amount of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor to the subject, wherein the subject is refractory or is resistant to a BTK inhibitor.
The method of claim 2, wherein the disease comprises cancer, an autoimmune disease, or an inflammatory disease.
The combination product according to claim 1, and the method according to claim 2 or 3, wherein the Bcl-2 inhibitor is a compound of formula I-A or a pharmaceutically acceptable salt or solvate thereof:

wherein:

A ₃ is

E ₃ is a carbon atom and
is a double bond; or

E ₃ is a -C (H) -and
is a single bond; or

E ₃ is a nitrogen atom and
is a single bond;

X ³¹, X ³² and X ³³ are each independently selected from the group consisting of –CR ³⁸= and -N=;

R ^31a and R ^31b taken together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered optionally substituted aliphatic ring; or

R ^31a and R ^31b taken together with the carbon atom to which they are attached form a 4-or 5-membered optionally substituted heterocyclo;

R ³² is selected from the group consisting of -NO ₂, -SO ₂CH ₃, and -SO ₂CF ₃;

R ^32a is selected from the group consisting of hydrogen and X;

R ³³ is selected from the group consisting of hydrogen, -CN, -C≡CH, and -N (R ^34a) (R ^34b) ;

R ^34a is selected from the group consisting of optionally substituted C _1-6 alkyl, optionally substituted C _3-6 cycloalkyl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl;

R ^34b is selected from the group consisting of hydrogen and C _1-4 alkyl;

R ³⁵ is selected from the group consisting of optionally substituted C _1-6 alkyl, heterocyclo, cycloalkylalkyl, and heterocycloalkyl;

R ^36a, R ^36c, R ^36e, R ^36f, and R ^36g are each independently selected from the group consisting of hydrogen, optionally substituted C _1-6 alkyl, optionally substituted C _3-6 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl;

R ^36b and R ^36d are each independently selected from the group consisting of hydrogen, C _1-4 alkyl, and halogen;

R ³⁷ is selected from the group consisting of optionally substituted C _1-6 alkyl, heterocyclo, heteroalkyl, cycloalkylalkyl, and heterocycloalkyl; and

R ³⁸ is selected from the group consisting of hydrogen and halogen.
The combination product according to claim 1 or 4, and the method according to claim 2 or 3, wherein the Bcl-2 inhibitor is selected from the group consisting of the following compounds or a pharmaceutically acceptable salt or solvate thereof:
The combination product according to claim 1 or 4, and the method according to claim 2 or 3, wherein the Bcl-2 inhibitor is the following compound or a pharmaceutically acceptable salt or solvate thereof:
The combination product according to claim 1 and the method according to claim 2 or 3, wherein the Bcl-2/Bcl-xL dual inhibitor is a compound of formula (I) , (II) , (III) or (IV) , or a pharmaceutically acceptable salt or solvate thereof:

wherein:

A ₁ ring is

X ₁₁, substituted or unsubstituted, is selected from the group consisting of alkylene, alkenylene, cycloalkylene, cycloalkenylene and heterocycloalkylene;

Y ₁₁ is selected from the group consisting of (CH ₂) _n-N (R ₁₁ ^a) ₂ and

Q ₁₁ is selected from the group consisting of O, O (CH ₂) _1-3, NR ₁₁ ^c, NR ₁₁ ^c (C _1-3 alkylene) , OC (=O) (C _1-3 alkylene) , C (=O) O, C (=O) O (C _1-3 alkylene) , NHC (=O) (C _1-3 alkylene) , C (=O) NH, and C (=O) NH (C _1-3 alkylene) ;

Z ₁₁ is O or NR ₁₁ ^c;

R ₁₁ and R ₁₂, independently, are selected from the group consisting of H, CN, NO ₂, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, OR ₁', SR ₁', NR ₁'R ₁”, COR ₁', CO ₂R ₁', OCOR ₁', CONR ₁'R ₁”, CONR ₁'SO ₂R ₁”, NR ₁'COR ₁”, NR ₁'CONR ₁”R ₁”', NR ₁'C=SNR ₁”R ₁”', NR ₁'SO ₂R ₁”, SO ₂R ₁', and SO ₂NR ₁'R ₁”;

R ₁₃ is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, OR ₁', NR ₁'R ₁”, OCOR ₁', CO ₂R ₁', COR ₁', CONR ₁'R ₁”, CONR ₁'SO ₂R ₁”, C _1-3 alkyleneCH (OH) CH ₂OH, SO ₂R ₁', and SO ₂NR ₁'R ₁”;

R ₁', R ₁”, and R ₁”', independently are H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, C _1-3 alkyleneheterocycloalkyl, or heterocycloalkyl;

R ₁' and R ₁”, or R ₁” and R ₁”' can be taken together with the atom to which they are bound to form a 3 to 7-membered ring;

R ₁₄ is hydrogen, halo, C _1-3 alkyl, CF ₃, or CN;

R ₁₅ is hydrogen, halo, C _1-3 alkyl, substituted C _1-3 alkyl, hydroxyalkyl, alkoxy, or substituted alkoxy;

R ₁₆ is selected from the group consisting of H, CN, NO ₂, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, heterocycloalkyl, OR ₁', SR ₁', NR ₁'R ₁”, CO ₂R ₁', OCOR ₁', CONR ₁'R ₁”, CONR ₁'SO ₂R ₁”, NR ₁'COR ₁”, NR ₁'CONR ₁”R ₁”', NR ₁'C=SNR ₁”R ₁”', NR ₁'SO ₂R ₁”, SO ₂R ₁', and SO ₂NR ₁'R ₁”;

R ₁₇, substituted or unsubstituted, is selected form the group consisting of hydrogen, alkyl, alkenyl, (CH ₂) _0-3-cycloalkyl, (CH ₂) _0-3-cycloalkenyl, (CH ₂) _0-3-heterocycloalkyl, (CH ₂) _0-3-aryl, and (CH ₂) _0-3-heteroaryl;

R ₁₈ is selected form the group consisting of hydrogen, halo, NO ₂, CN, CF ₃SO ₂, and CF ₃;

R ₁₁ ^a is selected from the group consisting of hydrogen, alkyl, heteroalkyl, alkenyl, hydroxyalkyl, alkoxy, substituted alkoxy, cycloalkyl, cycloalkenyl, and heterocycloalkyl;

R ₁₁ ^b is hydrogen or alkyl;

R ₁₁ ^c is selected from the group consisting of hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxy, and substituted alkoxy; and

n ₁, r ₁, and s ₁, independently are 1, 2, 3, 4, 5, or 6;

R ₂₁ is SO ₂R ₂’;

R ₂₂ is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl;

R ₂₃ is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl;

R ₂₄ is halogen, preferably fluoride, chloride;

R ₂₅ is halogen, preferably fluoride, chloride;

R ₂₆ is selected from H, halogen and alkyl, preferably fluoride, chloride, C _1-4 alkyl, more preferably methyl, propyl, isopropyl;

R _21b is H or alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl;

n ₂, r ₂ and s ₂ are independently 1, 2, 3, 4, 5 or 6, more preferably, r ₂ and s ₂ are both 2 and n ₂ is 3, 4 or 5, more preferably, all of n ₂, r ₂ and s ₂ are 2, and

R ₂' is alkyl, preferably C _1-4 alkyl, more preferably methyl, propyl, or isopropyl.
The combination product according to any one of claims 1, 4-7 and the method according to claim 2 or 3, wherein the Bcl-2/Bcl-xL dual inhibitor is selected from the group consisting of Compound 72 or Compound 88, or a pharmaceutically acceptable salt or solvate thereof;
The combination product according to claim 1, wherein the BTK inhibitor is selected from the group consisting of: Ibrutinib, ICP-022, Acalabrutinib (ACP-196) , BGB3111, ONO/GS-4059, Spebrutinib (CC-292 or AVL-292) , CNX-774, Olmutinib (HM61713, BI1482694) , M7583, HM71224, PCI-32765 Racemate, GDC-0853, ONO-4059, Zanubrutinib, RN486, PCI-32765, CGI-1746, QL47, LFM-A13, (±) -Zanubrutinib, SNS-062, BMS-935177, Btk inhibitor 2, Evobrutinib, Ibrutinib-biotin, BMX-IN-1, GDC-0834 and CB1763.
The combination product according to any one of claims 1, 4-9, wherein the combination product is in the form of a pharmaceutical composition.
The combination product according to any one of claims 1, 4-9, wherein the Bcl-2 inhibitor and the BTK inhibitor are each in a separate preparation, or wherein the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are each in a separate preparation.
The combination product according to any one of claims 1, 4-9, wherein the Bcl-2 inhibitor and the BTK inhibitor are administered simultaneously or sequentially, or wherein the Bcl-2/Bcl-xL dual inhibitor and the BTK inhibitor are administered simultaneously or sequentially.
The combination product according to any one of claims 1, 4-9, further comprising a pharmaceutically acceptable carrier, diluent or excipient.
The combination product according to any one of claims 1, 4-13, wherein the combined product is in the form of tablet, capsule, granule, syrup, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol, ointment, cream and injection.
Use of a Bcl-2 inhibitor and a BTK inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor in the manufacture of a medicament for the prevention and/or treatment of a disease selected from the group consisting of cancer, autoimmune disease and inflammatory disease.
A combination product for preventing and/or treating a disease, the combination product comprising a Bcl-2 inhibitor and a BTK inhibitor, or comprising a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor, and the disease is selected from the group consisting of cancer, autoimmune disease, and inflammatory disease.
A method of preventing and/or treating a disease, comprising administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of a Bcl-2 inhibitor and a BTK inhibitor, or an effective amount of a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor, wherein the disease is selected from the group consisting of cancer, autoimmune disease and inflammatory disease.
The method of claim 17, wherein the cancer is selected from the group consisting of acute myeloid leukemia (AML) , acute lymphoblastic leukemia (ALL) , diffuse large B-cell lymphoma (DLBCL) , follicular lymphoma (FL) , chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) , marginal zone lymphoma (MZL) , chronic myelogenous leukemia (CML) , mantle cell lymphoma (MCL) , Waldenstrom's macroglobulinemia (WM) , multiple myeloma (MM) , small cell lung cancer (SCLC) .
The method according to claim 17 or 18, wherein the Bcl-2 inhibitor, the Bcl-2/Bcl-xL dual inhibitor or a pharmaceutically acceptable salt or solvate thereof is administered in an amount of from about 0.0025 to 1500 mg/day.
The method according to claim 17 or 18, wherein the BTK inhibitor or a pharmaceutically acceptable salt or solvate thereof is administered in an amount of from about 0.0025 to 1000 mg per day.
The method according to any one of claims 17-20, wherein the subject is refractory or is resistant to a BTK inhibitor.